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Abstract 
 
The bacterial toxins hypothesis in multiple sclerosis postulates that bacterial toxins from the 
human nasopharynx access the central nervous system and are implicated in the disease.  
Dolosigranulum pigrum was originally found in acute multiple sclerosis tissues. This study 
seeks to determine if the organism is found in human nasal tracts and explores the 
relationship between Dolosigranulum pigrum infection and multiple sclerosis by measuring 
antibody to the bacterium in multiple sclerosis patients and matched controls. 
Eighty eight clinical specimens were cultured onto blood agar and analysed using rabbit 
anti-Dolosigranulum pigrum sera, and fluorescein isothiocyanate.  None tested positive for 
Dolosigranulum pigrum.  Dolosigranulum pigrum was looked for using a novel polymerase 
chain reaction test.   Thirty samples tested positive, 17 male, 13 female, with an age range 
from 8 days to 74 years.  Twelve were sent for sequencing, seven matched Dolosigranulum 
pigrum, two showed mixed amplicons and three produced signals not matching 
Dolosigranulum pigrum.  
Sixty five multiple sclerosis sera and matched controls were tested for  anti-
Dolosigranulum pigrum using a novel enzyme linked immunosorbant assay.   The multiple 
sclerosis group showed raised antibodies, significantly different to the controls,  p ≤ 0.001.  
Fifteen of the multiple sclerosis sera and controls were Western blotted. There were no 
common bands when compared with rabbit sera containing antibodies to Dolosigranulum 
pigrum.    
This study shows that Dolosigranulum pigrum is found in the nasal tract.  The elevated 
antibodies were not found to be anti-Dolosigranulum pigrum but their presence may be 
suggestive of bacterial products leaking from the nasal tract into the central nervous system. 
Further research into bacteria in the nasal tract is indicated.   Introduction of  markers into 
the nasal passages with subsequent tracking into the central nervous system by magnetic 
resonance imaging could provide evidence of a route by which bacterial molecules enter the 
central nervous system „behind‟ the blood brain barrier.   
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Foreword 
 
“The story of multiple sclerosis is like a history of medicine in minature.” 
Tracy J. Putnam (1938). 
 
 
 
Multiple sclerosis (MS) is now rarely fatal but the progressive loss of 
neurological function so frequently leads to overwhelming despair.  
"Why this deliberate, slow-moving malignity? . . . I am not  
offering up my life willingly - it is being taken from me piece 
 by piece, while I watch the pilfering with lamentable eyes.”  
Barbellion (1919). 
 
The above quotation is from the diary of Bruce Cummings, under his pseudonym 
W.N.P Barbellion, and details his struggle with MS in the first half of the last 
century.  The disease remains the major cause of incurable paralysis in young 
adults in the developed world, with an estimated 400,000 cases in Europe alone 
(Rotstein, Hazan, Barak & Achiron, 2006, pp. 511-516) at an estimated cost of 
€12.5 billion per year (Sobocki, 2007, pp. 1054-1064).  MS is characterised by 
patches of demyelination found in the central nervous system called plaques.  
These plaques may be found anywhere in the brain and spinal cord but appear to 
have a predilection for the cervical cord, brain stem, cerebellum and optic tracts. 
The inflammation of acute plaques appears to be located around small veins.  
Clinical signs and symptoms, characterised by motor and sensory deficits are, 
like the lesions, separated in time and space.  These symptoms may include a 
combination of: 
 Visual – Optic neuritis, Diplopia, Nystagmus 
 Motor – Muscle weakness, paralysis, spasms 
 Pain – Neuropathic, Musculoskeletal 
 Mobility – Ataxia, tremor, dizziness 
 Cognitive – Reduced mental speed, slow and slurred speech, difficulty in 
learning/remembering  
  2 
 Fatigue 
 Bladder and bowel problems 
 
There is no specific laboratory test for the disease and diagnosis is made 
clinically, aided by imaging techniques, evoked potentials and the finding of 
oligoclonal bands in the cerebrospinal fluid.  MS can be confused with strokes, 
Lyme disease, chronic fatigue syndrome and other diseases.  The prevalence of 
MS has been estimated to be 1 in 1000 and it has been calculated that 50% of 
patients are unable to walk without assistance 15 years after onset (Polman & 
Uitdehaag, 2000, pp. 490-494).  Yet despite over 170 years of intensive research 
the cause of MS, a specific diagnostic test for it, and a treatment, has eluded 
medical science.   
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Chapter 1:                                                
Introduction and literature review  
 
1.1 History of multiple sclerosis 
 
1.1.1 Naming and classifying the disease 
 
The first depiction of the distinctive patches of demyelination seen in multiple 
sclerosis (MS) appeared in 1838 in an atlas of pathology published by Robert 
Carswell (1838), a Scottish pathologist working in Paris.  Carswell, who 
probably never saw his subjects alive, did not include clinical details with his 
illustrations.  A link between the disease and its unusual microscopic appearance 
had to wait until 1842 when Jean Cruveilhier, who was also working in Paris, 
published his illustrations of the lesions along with clinical histories of the cases.  
In the next few years further important observations were made.  Eduard 
Reindfleisch (1863, pp. 274-483) provided further insights into the 
pathophysiology of MS  by observing that the lesions found in MS usually 
developed around small cerebral blood vessels, with plaques developing from 
these foci of chronic recurring peri-vascular inflammation.  In the same year 
Leyden (1863, pp. 114-116) noted that there was an excess of MS in women, 
with the disease first occuring in the third decade of life.  He postulated that MS 
was precipitated by disease, exposure to damp and cold or by emotional upsets. 
MS was finally characterized as a disease by Jean-Martin Charcot who initially 
named it „sclerose en plaques disseminées‟ in his seminal work of 1868 (pp. 557-
558, 566).  Charcot linked nystagmus, scanning speech and intention tremor to 
differentiate MS from other causes of paralysis, and then proceeded to describe 
the three cardinal pathological changes seen in MS: glial cell proliferation, 
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myelinated fibre degeneration and blood vessel changes (Figure 1.1).  He 
speculated that some insult led to glial cell proliferation which then resulted in 
the demylination of nerve cells. 
 
 
Figure 1.1. Charcot‟s Pathological Triad. (Courtesy F. Gay) 
a) Demyelination - multiple sclerosis plaque (P) showing demyelination in white 
matter (WM). Luxol fast blue stain for myelin. 
b) Glial cell proliferation - Macrophages in acute multiple sclerosis plaque (P). 
Monoclonal antibody Y1.83a, specific for macrophages + Horse Radish 
Peroxidase. 
c) Blood vessel inflammation -Vessel traversing acute multiple sclerosis tissue. 
CD4+ T cells (brown) and CD8+ T cells (purple). 
 
 
 
1.1.2 Clinical features and pathology 
 
There are many forms of MS (Whitaker & Mitchell, 1997, pp. 3-19) but the 
relapsing-remitting type, where attacks are followed by periods of remission 
lasting from a few days to months, is the commonest presentation (Figure 1.2A).  
These remissions may occasionally result in a complete recovery each time but 
normally the outcome is an improvement rather than the disappearance of 
symptoms.  A sub-group of patients with relapsing-remitting disease show a 
relatively benign course with little or no disability after 10 or more years (Figure 
1A).  Progressive relapsing-remitting (Figure 1B) is characterized by progressive 
continuous disease from the outset.    Secondary progressive MS (Figure 1C) is 
characterized by a steady worsening of symptoms.  Most sufferers with 
relapsing-remitting MS will go on to develop this form of MS, usually after 5-15 
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years.  About 10% of patients have primary progressive MS (Figure 1D) which is 
the most severe form, where the symptoms become steadily worse without 
relapses or remissions.  Rarely, patients have malignant MS with a rapidly 
progressive course of disease. 
 
 
 
Progress of disease 
                                                                                                                         
Time in years 
 
Figure 1.2. A representation of the four distinct clinical courses of multiple 
sclerosis. Figures show the progress of disease over time. (Whitaker and 
Mitchell, 1997). Figure (A) relapsing-remitting is characterized by alternating 
disease relapses and periods of full recovery or sequelae. Figure (B) progressive-
relapsing is characterized by continous disease which is progressive from the 
onset. Figure (C) secondary-progressive presents as a relapsing-remitting disease 
but converts to a progressive course at a later time point. Figure (D) primary-
progresses from onset, but has no definite acute relapses with or without 
remission. 
 
 
 
MS is defined by the formation of lesions known as plaques, defined areas of 
demyelination seen in the white and grey matter of the brain.  In normal brain 
tissue the neuronal axons are wrapped in myelin sheaths made from layers of cell 
membrane which are manufactured by oligodendrocytes, but in MS the myelin 
sheaths are stripped and axons degenerate.  Phagocytic macrophages dominate 
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these inflammatory lesions.  Demyelination results in the slowing of electrical 
impulses along the nerves, resulting in the focal neurological deficits that 
characterise MS.  Demyelinated lesions can be found throughout the CNS but 
certain areas seem more vulnerable: the optic nerve, brainstem, spinal cord and 
periventricular regions, with the involvement of these regions often being 
symmetrical (Ffrench-Constant, 1994, pp. 271-275).    
 
1.1.3 Epidemiology 
 
Exhaustive epidemiological studies of MS have been conducted (Acheson, 1985, 
pp. 3-27; Brody 1972, pp. 173-176) and the fundamental question of whether the 
risk of contracting the disease is determined primarily by environmental factors 
or by genetics has repeatedly been asked.  The answer has not been forthcoming, 
although it has been established that MS is not inherited as a single gene disorder 
(Compston, 1986, pp. 56-73; Roberts & Bates, 1982, pp. 287-293). 
 
1.1.3.1 Genetics and racial prevalence 
Studies have shown that there is only 28% concordance for MS amongst 
monozygotic twins and 2.5% amongst dizygotic twins (Ebers et al. 1986,  
pp. 1638-1642), indicating that genetic inheritance is not the major determinant 
and pointing to an important environmental factor in disease susceptibility.  This 
was further highlighted by a recent study of monozygotic twins discordant for 
MS (Barazini et al., 2010, pp. 1351-1356).  The researchers probed for 
differences in the genomes of three sets of monozygotic twins using DNA from 
their T cells and found no evidence of genetic, epigenetic or transcriptome 
differences to explain the disease discordance.  Studies into adopted siblings and 
half siblings were performed by Dyment, Ebers and Sadovick (2004, pp.104-
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110) to investigate if an environmental factor, such as a viral infection, may be a 
risk factor for MS, but there was no increased incidence in these groups. 
There appears to be racial differences in susceptibility to MS with it being rare in 
Hungarian gypsies, Huterites, Eskimoes and Orientals, whilst there is a high 
incidence in people of Fennoscandian origin (Ebers & Bulman, 1986, p. 108).  
Northern Europeans are associated with Human leucocyte antigen (HLA) A3, 
B7, DW2 and DR2 (Batchelor, Compston & McDonald, 1978, pp. 279-284) but 
the strengths of the association with MS are low, with the relative risks being in 
the region of 5.0 compared with 87.8 with HLA B27 and ankylosing spondolytis 
(Gay, 1991). 
Recent human genetic research into MS has found little evidence of a correlation 
with the disease.  The strongest association has been found with the HLA-DR 
genotype, particularly HLA-DRB1, which is present in northern Europeans but 
not in people of African descent, where MS is rare (Oksenberg et al., 2004, 
pp.160-167; Ramagopalan & Ebers, 2008, pp. 283-285).  Yet Hungarian gypsies 
have a high frequency of HLA-DR, but a low prevalence for MS (Gyodi et al., 
1981, pp. 1-12) and so a clear genetic marker of susceptibility to MS has yet to 
be detected. 
 
1.1.3.2 Geographical prevalence and migration 
Although there appears to be a global distribution of MS (Ebers & Sadovnick, 
1993, pp. 1-5) an association of MS prevalence with increasing latitude (Figure 
1.3) was noted by Limburg (1950, pp. 15-24) and has been confirmed by many 
studies (Hammond, English & McLeod, 2000, pp. 968-974; Miller, Hammond, 
McLeod, Pudie & Skegg, 1990, pp. 903-905; Wallin, Page & Kurtzke, 2004, pp. 
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65-71).  Dean (1967, pp. 724-730) showed that this cannot be accounted for by 
racial distribution when he found markedly lower rates of MS in decendents of 
white European populations in South Africa compared to the ancestral 
populations  in England and Holland.  This was confirmed by Miller and co-
workers in a study of Australia and New Zealand, (Miller et al., 1990, pp.903-
905) where they also found no correlation of MS with HLA-DR2 frequency.  In a 
review of this data, Compston (1990, pp. 821-823) observed that the highest 
prevalence rates for these antipodean communities, with ancestry primarily from 
the United Kingdom (UK), was half the frequency found currently in the UK. He 
concluded that the antipodean environment must have some sort of protective 
effect.   
Migration from a high risk (high latitude) to a low risk area results in a rate of 
MS intermediate between the native and host country (Baum & Rothschild, 
1981, pp. 420-428; McCall, Sutherland & Acheson, 1969, pp. 151-165; 
Sutherland, Tyrer, Eadie, Casey & Kurland, 1966, pp. 57-67), unless the 
individual migrates after the age of 15 when they carry their risk with them 
(Alter, Kahana & Loewenson, 1978, pp. 1089-1093; Alter, Leibowitz &  Speer, 
1966, 234-237; Alter, Okihiro, Rowley & Morris, 1971, pp. 122-130; Dean & 
Elian, 1997, pp. 565-568; Dean & Kurtzke, 1971, pp. 725-729; Detels et al., 
1978, pp. 386-393).  Furthermore, it was found that children of Indian, African 
and West Indian immigrants to England have a similar incidence of MS as the 
indigenous English population (Elian, Nightingale & Dean, 1990, pp. 906-911).  
The epidemiological evidence therefore points to an environmental factor, 
possibly an infective agent acquired during early adolescence that leads to 
symptomatic disease after a lengthy latency period. 
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Figure 1.3. Worldwide distribution of multiple sclerosis as of 1994. (Kurtzke, 
1997). Other risk = no data at present.  This world pattern has been attributed to 
latitude and not migrational effects (Miller et al., 1990). 
 
1.1.3.3 Epidemic multiple sclerosis 
Kurtzke and Hyllested (1975, pp. 213-215; 1988, pp. 190-227) reported three 
consecutive decreasing epidemics of  MS in the Faroe Islands, affecting native 
Faroese in the age group 11 to 45 years, from 1943 to 1973.  MS had not 
apparently been recorded prior to 1943, and they attributed the epidemics to the 
transmission of an infectious agent by occupying British troops during World 
War II.  Similar occurrences of epidemic MS were detected by  Kurtzke (1993, p. 
405) and by other researchers (Cook, Gudmundsson, Benedikz & Dowling, 1980, 
pp. 244-251; Cook et al., 1985, pp. 545-551) in Iceland, Shetland and the Orkney 
Islands.  However, these observations have since been challenged by Poser who 
attributed „epidemics‟ to problems with case ascertainment in these relatively 
isolated communities (Poser, Benedikz & Hibberd, 1992, pp. 143-152).  
 
  10 
1.1.4 Prospective aetiologies for multiple sclerosis 
 1.1.4.1 Autoimmune hypothesis 
Since the Second World War the theory that the demyelination seen in MS is due 
to an autoimmune T-cell mediated mechanism, although never proven, has 
through sheer repetition over the years become accepted as fact (McFarland & 
Martin, 2007, pp. 913-919).  Indeed all mainstream modern therapies are based 
on the assumption that this hypothesis is correct (Compston & Coles, 2002, pp. 
1221-1231). Reservations about this hypothesis occasionally emerge in the 
literature and have been heightened by the results of a survey of German, 
Hungarian and Polish MS patients (Greve, et al., 2008, pp.153-158).  The 
researchers failed to find polymorphisms in the CTLA4 gene region, where a 
single nucleotide polymorphism CT60 is associated with many autoimmune 
diseases such as Grave‟s disease and autoimmune diabetes. Barcellos 
controversially claimed a higher frequency of autoantibodies in families with MS 
(Barcellos et al., 2006, pp. 924-931) but Ramagopalan was unable to confirm the 
findings (Ramagopalan et al., 2007, pp. 604-610), and a recent study by Qui and 
colleagues (Qui et al., 2010, pp. 147-155) failed to find any correlation between 
auto-antibodies and MS. 
 
1.1.4.2 Viral hypothesis 
The epidemiology of MS indicates that there is an important environmental 
trigger (Acheson, 1985, pp. 3-87) which could be microbial in origin.  The search 
has focused on viruses, because of their well recorded latency.  It has been 
proposed that the virus acts through molecular mimicry and induces an 
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autoimmune response from the host leading to demyelination (Acheson, 1985, 
pp. 3-87; Wucherpfennig & Strominger, 1995, pp. 695-705).  
Molecular evidence of a straightforward antibody reaction to a viral antigen was 
gained by Owens and colleagues (Owens et al., 1998, pp. 236-243) but nothing 
has come of this research.  More recently an Italian study claimed to have found 
evidence of Epstein Barr Virus (EBV) in MS brain tissue (Serafini et al., 2007, 
pp. 2899-2912) and in another study EBV was also implicated in MS (Pender, 
2011, pp. 351-367) but these results have not been confirmed in other studies on 
EBV in MS (Hilton, Love, Fletcher & Pringle, 1994, pp. 975-976; Martin, 1997, 
pp. 280-283; Sargsyan et al, 2010, pp. 1127-1135; Willis et al, 2009, pp. 3318-
3328). 
 
1.1.4.3 Heterogeneity hypothesis 
By the beginning of the 21
st
 century the inability of researchers to establish a 
single cause of MS has led to the heterogeneity hypothesis (Lucchinetti et al., 
2000, pp. 707-717).  This claims that there are four distinct patterns of 
demyelination found in active demyelinating lesions in MS, and the researchers 
hypothesized that the disease consisted of four distinct diseases characterised by 
heterogenous pathogenetic mechanisms.  In other words, since evidence could 
not be found that either of the two favoured aetiological disease processes, 
autoimmunity or viral infection, was the cause of all cases of MS, then both 
could be responsible, depending upon certain unknown factors. This idea gained 
considerable impetus due to the discovery that Devic‟s disease, or neuromyelitis 
optica (NMO), formerly classified as a variant of MS, was in fact a separate 
autoimmune disease (Lennon et al., 2004, pp. 2106-2112). Heterogeneity has 
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since been challenged by a Dutch team (Breiji et al., 2008, pp. 16-25).  They 
found that there is uniformity in the active demyelinating lesions found in MS, 
and that any heterogeneity found in early lesions disappeared over time leaving 
an antibody and complement mediated myelin phagocytosis as the dominant 
general mechanism of demyelination.  Any heterogeneity is therefore found 
within cases and not between cases.  The problem with the heterogeneity 
hypothesis is nicely reviewed by Esiri (2009, pp. 39-41).  She concludes that 
further evidence is required to justify the claim that MS is other than a single 
distinct disease. 
 
 1.1.4.4 Spirochaetal hypothesis 
Pierre Marie, a pupil of Charcot who succeeded him in the Chair of Neurology at 
the Salpêtrière Hospital suggested in 1884 that MS might be caused by an 
infectious agent (Lamer, 1986, pp. 412-417).  The search proved fruitless until 
the beginning of the next century when similarities between MS and known 
spirochaetal diseases led to the hypothesis, popular between 1909 and the 1950s, 
that MS might be caused by these microbes.  The driving force for this 
hypothesis came from Germany (Schroeder, 1924, p. 785; Speer, 1921, p. 425) 
where spirocheatal organisms had been seen in central nervous system (CNS) 
tissue using silver stains.  The advent of Nazism and the cataclysm of World War 
II resulted in the disappearance of both researchers and their work after 1935.  
Gabriel Steiner, one of the few researchers who remained, emigrated to America 
after the war and continued his work on spirochaetes until 1954 (Steiner, 1952, 
pp. 342-372).  Acceptance of the spirochaetal hypothesis continued until 1957 
when Ichelson (1957, pp. 57-58) published an ill-fated paper in support of the 
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spirochaetal theory, only then to retract her findings admitting that her distilled 
water had been contaminated with spirochaetal organisms.  The long-term 
damage was devastating for spirochaetal research, with the influential MS 
Society refusing to fund further work and thus discouraging other bodies from 
supporting research, even to the present day (Gay & Dick, 1986, pp. 75-77). 
 
1.1.4.5 Chlamydial hypothesis 
Despite the great advances made in clinical microbiology since Steiner‟s work, 
no infective agent has been found.  It was thought that Chlamydia pneumoniae 
was implicated in MS development (Sriram, Mitchell & Stratton, 1998, pp. 571-
572) but this has since been challenged by the findings of a number of workers 
(Bowman, Roblin, Sundstrom & Hammerschlag, 2000, p. 265; Furrows et al., 
2004, pp. 152-155; Hammerschlag et al., 2000, pp. 4274-4276). 
 
1.2 Bacteria, sinusitis and multiple sclerosis 
 
1.2.1 Oligoclonal bands 
In the 1940s it was discovered that the cerebrospinal fluid (CSF) of MS patients 
contained an increase in gamma globulins which on electrophoresis show highly 
restricted banding (Kabat, Moore & Landow, 1942, pp. 571-577).  These 
oligoclonal bands of IgG are found in high concentrations in greater than 95% of 
patients presenting with MS suggesting an inflammatory immune response to a 
foreign antigen.  They are, however, not normally found in the serum of MS 
patients, suggesting that an antigen has entered the central nervous system (CNS) 
provoking a B-cell mediated immunological reaction.  Oligoclonal bands are one 
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of the few consistent and observable features of MS, and although they are used 
as a disease marker the reason for their production remains a mystery.  They are 
not specific for myelin, or other “self” antigens, and appear to be unrelated to 
micro-organisms (F.W. Gay, 2007, pp. 105-112).  However, iso-electric focusing 
of MS CSF followed by immuno-blotting with Staphylococcus aureus antigens 
resulted in evidence that some of the oligoclonal antibodies were S. aureus 
specific (Jorge, 1995).  
 
1.2.2 Multiple sclerosis, optic neuritis and sinusitis 
Optic neuritis arises from an inflammation, and accompanying demyelination, of 
the optic nerve.  This results in blurred vision, loss of visual acuity, 
dyschromatopsia, complete or partial blindness, and pain behind the eye.  It 
usually appears unilaterally, and in the 15-50 year age group it is the most 
frequently presenting symptom of the onset of MS (Hutchinson, 1976, pp. 283-
289; McAlpine, 1972, pp. 148-163).   
The idea that optic neuritis was in some way linked to paranasal sinusitis 
appeared in the literature throughout the 18
th
 and 19
th
 centuries (White, 1917, pp. 
891-899), and in the early 20
th
 century a series of reports led to the belief that 
infections in the posterior ethmoidal and sphenoidal air sacs led to optic neuritis 
(Crane, 1927, pp. 201-240). 
By the end of the 1920s a considerable body of evidence had built up linking 
optic neuritis and sinus disease (Thomson, 1929, pp. 248-261).  When Herzog 
(1928, pp. 292-321) histologically examined twelve cadavers he discovered 
considerable variation in the structure and density of the bone separating 
sphenoidal and ethmoidal cells from the optic canal.  Reviewing sinus tissue 
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from cases of optic neuritis he observed that even where the epithelium appeared 
to be healthy the mucosa showed evidence of chronic inflammatory 
degeneration.  Oliver and Crowe (1927, pp. 503-525) and McMahon (1926, pp. 
310-333) corroborated his findings.  It became apparent that the structure of the 
bony wall of the optic canal was an important determinant of the outcome of any 
mucosal infection.  These findings were especially interesting when added to the 
evidence of anatomical research performed by Onodi (1908, pp. 1-61) and Van 
Alyea (1941, pp. 225-253).  They found that during the second decade of life 
excavation of the sphenoid bone led to the formation of recesses which 
penetrated the middle cranial fossa.  This resulted in the optic nerve meninges 
being separated from the sinuses by thin layers of bone through which the sinus 
mucosa sometimes herniated, leading Onodi (1908, pp. 1-61) to speculate that a 
pathway might be opened for chronic infections of the sinuses to extend into the 
CNS (Figures 1.4 and 1.5).  Kramer and Som (1940, pp. 744-770) were later to 
demonstrate this in cases of „cryptogenic‟ bacterial meningitis. 
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Figure 1.4. Median sagittal section through the sella turcica (arrow) showing 
deeply penetrating sphenoidal (sph) and ethmoidal (eth) cells, with paper thin 
walls. Onodi collection. Royal College of Surgeons of England. 
 
 
 
Figure 1.5. Localised defect in the wall of the optic canal (arrow), 
communicating with spheno-ethmoidal sinus. Onodi collection. Royal College of 
Surgeons of England. 
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Harris Vail (1931, pp. 846-863) using X-rays and surgical exploration implicated 
posterior sinus infection as a cause of optic neuritis.  He also made the 
observation that optic neuritis, like sinusitis, was commoner in the colder months 
of the year, with patients often recalling having had coryza or „flu‟ prior to the 
attack.  In 1926 McMahon (pp. 310-333) established that spheno-ethmoiditis was 
twice as common in females, with a steep rise in the third decade of life followed 
by a gradual decline in the fourth and fifth decades.  This seemed to show that 
spheno-ethmoiditis and optic neuritis were clinically related and shared 
distinctive epidemiological features.   
Derek Vail in 1938 (pp. 383-394) suggested that the posterior sinuses might form 
a portal through which toxins or viruses could enter, such that MS, optic neuritis 
and optochiasmatic arachnoiditis might be part of the same pathological process. 
During the period between the world wars it was perceived that surgical drainage 
of the posterior sinuses relieved the condition of optic neuritis, even though 
Brunner (1941, pp. 903-929) pointed out that many cases of optic neuritis 
resolved spontaneously if left alone (F.W. Gay, 2007, pp.105-112).   It was found 
that in most instances optic neuritis led to MS, with figures as high as 75% in 
temperate latitudes (Shibasaki, McDonald & Kuroiway, 1981, pp. 253-271).  It 
was thus surmised (incorrectly) that since optic neuritis was caused by MS, it 
could not be caused by sinusitis.  The implication was that the cause of MS was 
known, with sinusitis being excluded as a possible cause.    
 
1.2.3 Evidence for a link between sinusitis and multiple sclerosis 
There are a number of clinical and epidemiological similarities between these 
two diseases.  Both are chronic diseases characterised by exacerbations and 
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remissions.  Both MS and sinusitis have been shown to be activated by minor 
viral respiratory infections (Anderson, Lygner, Bergstrom, Anderson & Vahlne, 
1993, pp. 417-422; Johnson, 1994, pp. S54-S60; Panitch, 1994, pp. S25-S28; 
Sibley, Bamford & Clark, 1984, pp. 14-24).  
One of the most distinctive features of MS is the age attack distribution which 
shows few cases before the age of 15 years with rates rising rapidly to the age of 
30 years and then declining again with relatively few cases after the age of 35 
years. Despite geographical differences in incidence, this age-attack curve 
remains remarkably constant and both Brody (1972, pp. 3-27) and Acheson 
(1985, pp. 173-176) contended that it was unlike any contagious disease known.  
In 1986, an association between MS and chronic sinusitis, with the peak in sinus 
infection occurring in the year immediately preceding the first recorded episode 
of MS, was noted by Gay, Dick and Upton (1986, pp. 815-819).  It was also 
noted that sinusitis, like MS, showed a tendency to affect females more 
frequently than males (a ratio of 2:1) and at an earlier age (Gay, Dick & Upton, 
1986, pp. 815-819, Callaghan, 1986, p. 160).  Both MS and sinusitis are 
seasonal, showing a peak of attacks that coincides in the spring and summer in 
both the northern and southern hemispheres (Auer, Schumann, Kumpfel, Gossi 
& Trenkwalder, 2000, pp. 276-278; Callaghan, 1986, p. 160-161; Gay, Dick & 
Upton, 1986, pp. 815-819; Salvi et al., 2010, p. 105; Sibley, Bamford & Kent, 
1983, pp. 14-24; Tremlett, et al., 2008, pp. 271-279).   The incidences of both 
diseases increases with increasing latitude, possibly indicating a relationship to 
climate (Acheson, 1985, pp. 3-46; Gunderson & Häväg, 1971, pp. 939-943), and 
both show the carriage of risk, fixed during the later teenage years, on migration 
from high to low incidence locations.  In chronic sinusitis this is linked to 
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continuing mucosal damage to cells caused by repeated attacks of low grade 
infection (F.W. Gay, 2007, pp. 105-112).  Since the sphenoidal sinuses undergo 
their major development post puberty, mucosal damage of these sinuses by 
microbes would be limited in children, and if MS and chronic sinusitis are linked 
this would also explain the onset of MS after puberty (Dick and Gay, 1988, pp. 
25-35).   Furthermore, if there is an association between the two diseases then a 
person migrating from a high-risk area before the age of 15 years to a warm 
climate where the risk of MS is low (Martin, 1967, pp. 1079-1098), would avoid 
the risk of chronic sinus damage, and therefore would not carry the associated 
high risk of MS.  In 1988 Dick and Gay (pp. 25-35) postulated that a microbe or 
its products could enter the CNS via the posterior paranasal sinuses in MS 
patients, but since then nose to brain transmission of transportable toxins released 
into the mucosal tissues by bacterial flora in the paranasal sinuses, has received 
little attention.  Hawkes and co-workers (Hawkes, Shepherd & Daniel, 1999, pp. 
473-480) noted the impaired sense of smell in a number of neurodegenerative 
diseases such as Alzheimer‟s disease and Parkinson‟s disease.  Impairment of 
olfactory function is also a feature of early active MS (Lutterotti et al., 2011, pp. 
964-969) and could be indicative of a connection between the nose and brain. 
 
1.2.4 Bacterial infections and multiple sclerosis 
Whilst the search for viruses continues, bacterial causes of MS have been largely 
ignored.  This omission is puzzling as bacteria are known to produce an array of 
products and have been implicated in „autoimmune‟ molecular mimicry (Moran, 
Prendergast & Appelmelk, 1996, pp. 105-115).  In recent years many diseases 
with previously unknown aetiologies have been shown to be caused by bacteria. 
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These include Legionnaire disease (McDade et al., 1977, pp. 1197-1203), 
haemolytic-uremic syndrome (Griffin & Tauxe, 1991, pp. 60-98) and Lyme 
Disease (Steere et al., 1983, pp. 733-740).  The dogmatic assumption of a viral 
aetiology for MS was summed up by Marshall (1988, pp. 89-92) as consisting of 
the argument “MS is a viral disease, we do not know which virus yet we will find 
the right one someday.”  An example of the dangers of such tunnel vision can be 
seen with gastritis and acid-peptic ulceration.  Generations of physicians were 
taught that the extremely acidic environment of the stomach meant that bacteria 
could not survive there, so that although bacteria were seen in gastric acid-peptic 
ulcer biopsies they were cursorily dismissed as transient contaminants.  Even 
when Marshall and Warren (1984, pp. 1311-1315) presented evidence of  
Helicobacter pylori as the cause of chronic ulcerative gastritis they were ignored 
or  disbelieved for a decade until the evidence, largely due to the efficacy of 
antibiotics,  eventually proved irrefutable.  
A review by Trapp (2004, pp. 455-457) on the lack of progress in establishing 
the pathogenesis of MS states that there is a „missing link‟ in the understanding 
of MS.  If this „missing link‟ is the presence and processing of microbial antigens 
then bacterial products provide the best fit.  Bacteria produce transportable 
antigens such as β toxin (sphingomyelinase) which are complement-fixing and 
toxic for oligodendrocytes, resulting in cell apoptosis (Esen et al., 2011, pp. 431-
439).  Reports of the presence of Gram positive cell wall lipotechoic acid in MS 
plaque macrophages (Schrijver et al., 2001, pp. 1544-1554; Visser et al., 2006, 
pp. 1671-1685) suggest that bacterial antigens may be involved, especially as 
peptidoglycans have been implicated in chronic inflammation (Dziarski, 2003, 
pp. 1793-1804). 
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There have been some studies performed to investigate if bacterial infections can 
initiate relapses of MS (Sibley, Bamford & Clark, 1985, pp. 1313-1315; 
Buljevac, et al., 2002, pp. 952-960) but more have been performed on 
experimental autoimmune encephalomyelitis (EAE), the animal model for MS.  
Enterotoxins from Staphylococcus aureus, which can act as T-cell activating 
superantigens, can exacerbate or induce EAE (Matsumoto & Fujiwara, 1993, pp. 
268-278; Schiffenbauer, Johnson, Butfiloski, Wegrzyn & Soos, 1993, pp. 8543-
8546; Soos, Hobeika, Butfiloski, Schiffenbauer & Johnson, 1995, pp. 6082-6086; 
Soos, Mujtaba, Schiffenbauer, Torres & Johnson, 2002, pp. 30-34).   
Additionally a worsening of EAE in mice infected with Streptococcus 
pneumoniae has been reported (Herrman et al., 2006, pp. 4841-4848).  This 
ability of pathogens to influence the course of autoimmune diseases is due to 
their intrinsic activation of Toll-like receptors (TLRs) which recognise specific 
patterns of microbial components and regulate the activation of innate and 
adaptive immunity (Prinz et al., 2003, pp. 195-199; Takeda & Akira, 2005, pp. 1-
14).  Bacterial lipopolysaccharides are potential modifiers of autoimmune 
inflammation (Hamada, Driscoll, Kies, & Alvord, 1989, pp. 275-284; Segal, 
Chang & Shevach, 2000, pp. 5683-5688; Segal, Klinman & Shevach, 1997, pp. 
5087-5090, Visser et al., 2005, pp. 808-816) and are able to activate the innate 
immune system via specialized receptors such as TLRs situated on antigen 
presenting cells (Takeda & Akira, 2005, pp. 1-14). Although there is little data 
on Gram positive bacteria modulating EAE, exacerbation of MS after active 
immunization with a pneumococcal vaccine has been reported (Tan, 2002, pp. 3-
9).  Herrmann et al. (2006, pp. 4841-4848) have postulated that this exacerbation 
is Toll-like receptor 2 (TLR2) dependent but T cell independent, and speculated 
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that the action of S.  pneumoniae or other bacteria on the immune system in MS 
is greatest in the subclinical phase of infection and occurs prior to the 
manifestation of an MS event.   
 
1.2.5 Possible mechanisms for a bacterial aetiology 
If it is accepted, then, that there could be a bacterial cause of MS, why has the 
organism not yet been identified?  There are several reasons why this could be. 
The bacteria could be fastidious organisms that will not grow on conventional 
bacteriological culture media. Bacteria which are now well recognized as human 
pathogens such as Campylobacter jejuni (Dekeyser, Goussuin-Detrain, Butzler & 
Sternon, 1972, pp. 390-392) and Legionella pneumophila (McDade et al., 1993, 
pp. 1197-1203), and more recently Helicobacter heilmannii (Sykora, Hejda, 
Stozicky, Siala & Schwarz, 2004, pp. 707-709) were not identified as causes of 
human disease until specialized techniques were employed.  Similarly, the 
organism could fail to be isolated because of a slow growth rate, as happened 
with Bartonella henselae  the cause of cat scratch fever (Zangwill et al., 1993, 
pp. 8-13) bacillary angiomatosis (Koehler, Quinn, Berger, LeBoit & Tappero, 
1992, pp. 1625-1631) and with submasseteric abscesses with Mycoplasma 
salivarium  
(Grisold et al., 2008, pp. 3860-3862).   
Conversely the organism may be relatively easily grown but located in a region 
of the body with a large and complex normal flora.  Such pathogens usually exert 
their effect by toxin production such as Escherichia coli O157:H7, which was 
not routinely looked for as a cause of food poisoning until clusters of bloody 
diarrhoea led to its recognition as a pathogen (Besser et al., 1993, pp. 2217-2220) 
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and more recently Escherichia coli O104: H4, which produces a Shiga-like toxin 
(Muniesa, Hammerl, Hertwig, Appel & Brussow, 2012, pp. 4065-4073). 
The bacterial pathogen potentially causing the disease may also do so as the 
result of uncommon sequelae of common infections.  The effects may be distant 
in both location and time.  Campylobacter enteritis can initiate Guillain-Barré 
syndrome in 1 case out of 2000 infections (Mishu & Blaser, 1993, pp. 104-108).  
Blaser speculated as long ago as 1994 (pp. 144-145) that there is plenty of 
evidence of bacterial causes of chronic inflammatory disease, and if a 
demyelinating disease such as Guillain-Barré syndrome can be triggered by a 
bacterial infection (Hughes & Cornblath, 2005, pp. 1653-1666) then why not 
MS?  Speculation of a bacterial aetiology has foundered on the inability to isolate 
an organism by bacterial culture, and this was thought by advocates of this 
hypothesis to be due to technological shortcomings.   The development of 
molecular techniques, especially using primers of the 16S rRNA genes of 
bacteria, gave fresh impetus to researchers looking to discover bacterial causes 
for diseases. The use of universal primers to investigate diseases of unknown 
aetiology such as MS was an attractive proposition (Grieson, Loeffelholz, 
Purohit & Leong, 1994, pp. 335-351; Relman, Schmidt, MacDermott & Falkow, 
1992, pp. 293-301).  Universal primers rely on the fact that some areas of the 16S 
rDNA are conserved among all bacteria, while some are conserved within a 
genus or a larger group, as well as there being areas unique to individual 
bacterial species.  The use of universal primers to amplify all bacteria is 
attractive in practice but is useful only for those specimens with a relatively high 
bacterial concentration.  Bacteria and their DNA are ubiquitous so that there is a 
background level of bacterial DNA contamination.  Lindsey and Patel (2008, pp. 
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147-152) estimated this background level of contamination in their laboratory to 
be 200 genomes per reaction in their laboratory and found that the CSF of MS 
patients in their study was never higher than this level.  After sequencing the 
PCR products, they found that the most common contaminants were uncultured 
species of Pseudomonas and E. coli. Other researchers also encountered 
contamination problems when using universal primers (Corless, Guiver, Borrow, 
Edwards-Jones, Kaczmarski & Fox, 2000, pp. 1747-1752; Grieson, Loeffelholz, 
Purohit & Leong, 1994, pp. 335-351).  Semi-universal primers, using a nested 
PCR, have been used to examine MS CSF (Lindsey & Patel, 2008, pp. 147-152) 
but despite the increased sensitivity of this technique no DNA of spirochaetes, 
Campylobacter, Mycoplasma, Chlamydia, Bartonella, Mycobacteria or 
Streptococcus were found.  Lindsey and Patel did not rule out a bacterial 
aetiology for MS, but concluded that until they had an idea of what the causative 
organism was likely to be, such an approach was unlikely to be successful as the 
number of potential candidates was so large. 
Before Steiner (1952, pp. 343-372) proposed his spirochaetal hypothesis of MS, 
Dawson (1916, pp. 517-740) had hypothesized that bacterial toxins intermittently 
disseminated in the CSF could damage the blood brain barrier and result in 
perivascular demyelination, and Vail (1938, pp. 383-394) suggested that bacterial 
toxins could diffuse into the CNS via lesions in the paranasal sinuses.  
Gadolinium-enhanced nuclear magnetic resonance imaging showed that foci of 
blood-brain barrier leakage were the earliest detectable change in the central 
nervous system in MS (Grossman et al., 1988, pp. 117-122). 
The most compelling model put forward though is by Gay (F.W. Gay, 2007, pp. 
105-112).  This bacterial toxins hypothesis postulates that an intermittent leakage 
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of a mixture of bacterial toxins from the posterior paranasal sinuses into the CNS 
results in MS. As already detailed in section 1.2.3 there are marked similarities 
between sinusitis and MS, and Gay‟s hypothesis links the two conditions. 
 
1.3 The bacterial toxins hypothesis 
 
1.3.1 Association of bacterial toxins with sinusitis and multiple 
sclerosis 
 
As mentioned in section 1.2.3 there are marked similarities between sinusitis and 
MS, and the possibility of a link between the two diseases. Anatomical and 
physiological studies show that the posterior paranasal sinuses lie close to the 
optic nerve meninges and the contiguous structures of the spinal cord and brain.  
Furthermore the sub-mucosa of cells in the ethmoidal and sphenoidal sinuses 
often lie on the optic nerve and adjoining basal dura without the protection of 
intervening bone (F.W. Gay, 2007, pp. 105-112).  Cranial nerves, blood vessels 
and lymphatics also pass through the structures of this region thus providing an 
opportunity for the spread of bacterial products from the sinuses into the CNS 
(Esiri & Gay, 1990, pp. 3-8; Foldi, 1977, pp.121-124; Rennels, Gregory, 
Blaumanis, Fijimoto & Grady, 1985 pp. 47-63).  Studies have shown that both 
spinal and cranial nerve sheaths are able to carry bacterial toxins centrally to the 
CNS (Orr & Rose, 1914, pp. 271-340; Wright, 1953, p. 319).  
 
1.3.2  The blood-brain barrier 
It has long been known that there is a blood-brain barrier which shields the CNS 
from the immune system.  This „immunological privilege‟ (Billingham & 
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Boswell, 1953, pp. 392-406) was thought to be due to the CNS lacking a 
lymphatic drainage system.  However,  it is now well established that a variety of 
drugs, some possessing molecules too large to pass the blood-brain barrier 
rapidly access the CNS when administered intranasally (Hanson & Frey, 2008, 
pp. 1-6).   It has become clear that there are channels surrounding the cranial 
nerves and the cerebral blood vessels that provide a bi-directional flow between 
the CNS tissues and the local lymphatic system (Becher, Prat & Antel, 2000, pp. 
293-304; Esiri & Gay, 1990, pp. 3-8; Rennels et al., 1985, pp. 47-63). Protein 
tracers have shown that there are bidirectional links beween the extracellular 
fluid compartment of the CNS and the lymphatic system of the head and neck via 
sheaths in the meningeal vessels and perineural cranial nerves (Esiri & Gay, 
1990, pp. 3-8; Johansson, 1995, pp. 1-19; Rennels et al., 1985, pp. 47-63).  These 
channels permit the CNS to mount an immunological response to antigens within 
the CNS tissues.  This means that it is possible for antigens being processed in 
the mucosa of the nasopharynx to drain into the CNS and be processed by the 
immune cells in the meninges and perivascular space.  Toxins released by 
microbes in the sinuses can therefore enter the CNS and gain access to the brain 
and spinal cord (F.W. Gay, 2007, pp. 105-112).  The inflammation seen in MS in 
the trans-cisternal trigeminal nerve that was observed by Orr and Rose in 1914 
(Orr & Rose, 1914, pp. 271-340) may therefore be the result of ascending 
lymphatic drainage from the nasopharynx.  The clinical, epidemiological and 
pathogenic similarities between MS and nasopharyngeal sinusitis is thus 
consistent with the bacterial toxins hypothesis (F.W. Gay, 2007, pp. 105-112). 
It has been realised for some time that in MS apparantly normal myelinated CNS 
tissue located some distance from plaques show significant abnormalities.  Blood 
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vessels traversing myelinated white matter show inflammatory cell perivascular 
cuffing (Adams, 1975, pp. 165-182; Adams, 1989, pp. 130-139), and activated 
astrocytes (McKeown & Allen, 1978, pp. 471-482).  McKeown and Allen (1978. 
pp. 471-482) postulated that these changes represented the primary pre-
demyelinating process.  In immunocytochemical studies using early post-mortem 
tissue (Barnett & Prineas, 2004, pp. 458-468; Gay, 2006; pp. 234-240; Gay, 
Drye, Dick & Esiri, 1997, pp. 1461-1483; Groome, Hayes, Woodroofe, Glynn & 
Cuzner, 1987, pp. 463-467; Li, Cuzner & Newcombe, 1996. pp. 207-213; 
Sanders, Conrad & Tourtellotte, 1993, pp. 207-216) areas of normal appearing 
white matter located in perivascular, subependymal and subpial parenchyma 
were populated by HLA DR+ microglia  with clear morphological evidence  of 
cellular  activation.  These lesions may represent primordial plaques as the 
microglia show evidence of containing myelin-peptide and basic protein (F.W. 
Gay, 2007, pp. 105-112).  These „activated‟ regions were found in the 
parenchyma and were virtually devoid of T-cells as well as showing no evidence 
of plasma-protein leakage suggesting an intact blood brain barrier (Esiri & Gay, 
1997, pp. 173-186; Gay et al., 1997, pp. 1461-1483; Gay, 2006, pp. 234-240).  
Some lysis of myelin appears in this region but the opsonisation of the sheath 
with immunoglobulin and complement sometimes seen in plaques (Storch et al., 
1998, pp. 465-471) is absent (Gay et al., 1997, pp. 1461-1483; Gay, 2006, pp. 
234-240).  In some areas of microglial activation, co-locating C3d and IgG were 
found on the microglial cell membranes suggesting the capture of immune 
complexes by these cells (Esiri & Gay, 1997, pp. 173-186; Gay et al., 1997, pp. 
1461-1483; Gay, 2006, pp. 234-240).  In these studies, C3d and IgG were also 
found on HLA DR+ macrophages in the Virchow Robin (VR) spaces of vessels 
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crossing normally myelinated tissues, as well as being found free on the glia 
limitans.  This has led to speculation that extrinsic complement-fixing antigens, 
such as bacteria or bacterial toxins, are being processed in the VR spaces and an 
excess of the antigens could then spill over across the glia limitans into the 
surrounding parenchyma leading to a local activation of perivascular microglia 
and resulting in the iniation of myelin damage (Esiri & Gay, 1990, pp. 3-8; Gay, 
2006, pp. 234-240).   
 
1.3.3  Evidence for bacterial toxins in multiple sclerosis 
 
Histological stains revealing erosion and lysis of myelin sheaths that were 
suggestive of a primary lytic factor were observed as long ago as 1955 
(Lumsden, 1955, pp. 208-239). In experimental allergic encephalomyelitis 
(EAE), which is often employed as a model for MS, myelin loss is thought to be 
due to the „bystander‟ effect caused by proteinases produced by T cells (Brosnan, 
Cammer, Norton & Bloom, 1980, pp. 235-237).   Yet Raine (1997, pp. 243-286) 
has highlighted the problem of extending this hypothesis to MS, namely none of 
the chronic and inflammatory diseases of the CNS induce plaque formation. 
Barnet and Prineas came to the same conclusion and suggested that there was a 
specific pathogenic attack on the myelin (Barnett & Prineas, 2004, pp. 458-468). 
So what evidence is there for an extrinsic antigen, such as a bacterial toxin, being 
involved in the pathology of MS? 
A powerful polyclonal B-cell response has been found in the CNS in MS with 
antibodies produced to a variety of microbial and other antigens (Walsh & 
Tortellotte, 1983, pp. 275-358) that is characteristic of the response to bacterial 
cell wall polymers (Räsänen & Arvilommi, 1981, pp. 712-717). This response is 
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accompanied by repeated bursts of oligoclonal antibody production that coincide 
with disease activity measured by computerised tomography (CT) and magnetic 
resonance imaging (MRI) scans (Sharief & Thompson, 1991, pp. 181-195).  This 
is suggestive of stimulated B lymphocytes reacting with T cell independent 
antigens such as bacterial cell wall polymers.  The random release of bacterial 
antigens into the CNS should result in changes of the oligoclonal banding pattern 
during the course of MS, something which Thompson, Kaufmann and Rudge 
(1983, pp. 547-550) have observed.  
In 1991 small plaques in early MS were found to contain particulate material 
within macrophages and astrocytes, on which complement and immunoglobulins 
were co-located (Gay & Esiri, 1991, pp. 557-572) (Figure 1.6).  These were 
absent in chronic MS, indicating that the inflammatory changes had a degree of 
specificity that could be related to the antigens within the macrophages and 
astrocytes. Further studies by Gay (2006, pp. 234-240) indicated the presence of 
a diffuse, complement-fixing antigen.  This was located in the Virchow-Robin 
spaces.  It was speculated that a bacterial lipase may be the antigen. Exogenous 
superantigens have been of interest in this context.  These are a heterogeneous 
group of cellular and transportable molecules that result in the non-specific 
proliferation of T and B cells by binding to the Vβ region of the T cell receptor 
and the α chain of the major histocompatability complex (MHC) (Friedman, 
Posnett, Tumang, Cole & Crow, 1991, pp. 468-480). Although Rudge speculated 
that an unknown retrovirus could produce them in MS patients (Rudge, 1991, pp. 
853-855) superantigens are produced by many Gram positive organisms, such as 
streptococci and staphylococci, and Kotb (Kotb, 1995, p. 416) speculated that 
bacterial superantigens may cause MS. 
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Figure 1.6. Immunocytochemistry of acute multiple sclerosis tissues.  
Co-locating IgG and C3d. Immune complexes are located on the membranes of 
activated macrophages. Anti-human IgG-TRITC; anti-human C3d-FITC (Gay, 
Drye, Dick & Esiri , 1997). 
 
 
1.4 Dolosigranulum pigrum 
 
1.4.1 Initial isolation and identification 
Dolosigranulum pigrum was first isolated in 1988 at the Microbiology 
Department of Colchester General Hospital (Aguirre, Morrison, Cookson, Gay & 
Collins, 1993, pp. 608-612) from spinal cord tissues.  The tissues were obtained 
at a coroners post mortem from a case of suicide (hanging) of a newly diagnosed 
case of  MS, one week after onset of  an acute attack of the disease.  The tissue 
had been frozen in liquid nitrogen at post-mortem and then stored at -80°C, and 
was donated by the Institute of Neurology, National Hospital for Neurology and 
Neurosurgery, Queens Square, London WC1N 3BG to Dr FW Gay, who in 1988 
was conducting research at the Colchester Hospital laboratory into the possible 
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role of bacterial infections in MS.  Gay and co-workers (Gay et al., 1997, pp. 
1461-1483) found groups of C3d-IgG coated 1.0-1.5 μm ovoid bodies (Figure 
1.4 ) resembling bacterial cells scattered throughout the meningeal tissues of the 
spinal nerve roots, and in the phagocytic vacuoles of activated macrophages 
within MS lesions (Gay et al., 1997, pp. 1461-1483).   
Although bacterial cells are found as post mortem contaminants, the presence of 
surface complement and immunoglobulin in this case suggested that the oval 
bodies (if bacterial in nature) had invoked an ante-mortem immune response.  
The fact that the tissue had been snap frozen during autopsy and then stored at  
-80°C raised the possibility that bacterial cells within tissue would remain viable, 
and so, in an attempt to identify the organism, cut surfaces of the frozen tissue 
blocks were impressed onto the surface of Columbia agar with 5% horse blood, 
nutrient agar and chocolate agar, and incubated at 37°C, aerobically, 
anaerobically and with 5% carbon dioxide.  Micro-colonies of less than 0.5 mm 
were seen after 72 h around the periphery of the impressions on the aerobic blood 
and chocolate agar plates. Growth was also seen on the nutrient agar plates.  Sub 
cultures were made on Columbia agar with 5% horse blood and incubated at 
37°C. After 48 h, a faint growth was visible that after a further 24 h appeared as 
non-haemolytic dry, grey/white microcolonies less than 1.0 mm in diameter.  
After 5 days incubation the colonies were convex, white and glossy and 1.0 mm 
in diameter and demonstrated α haemolysis (Figure 1.7). There were tiny 
colonies formed that upon sub-culture resembled the main growth.  The plates 
were then incubated for a further 3 days at an ambient temperature of 18°C and 
developed β haemolysis (Figure 1.8).  
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Figure 1.7. Dolosigranulum pigrum on aerobic Columbia blood agar showing α 
haemolysis after 5 days aerobic incubation at 37°C. 
 
 
 
 
Figure 1.8. Dolosigranulum pigrum on aerobic Columbia blood agar showing β 
haemolysis after 8 days aerobic incubation at 37°C and 3 days at 18°C. 
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On two further occasions, using the same methods, the organism was isolated in 
pure culture and was sub-cultured for identification by the author (F.M. Jorge, 
November, 1989). The bacteria were catalase negative, Gram positive cocci,   
1.0-1.5 μm  in size, ovoid in shape and arranged in clumps. Using the API 20 
STREP system (bioMerieux), positive reactions were seen with the pyrrolidonyl 
arylamidase, leucine aminopeptidase and arginine dihydrolase tests.  The profile 
did not fit with any bacteria on the API database, but was closest to Gemella 
haemolysans. These findings were confirmed by API bioMerieux (UK) Limited, 
and by the Laboratory of Hospital Infection, Colindale, London.  
 
1.4.2 Characterization and naming of Dolosigranulum pigrum 
The bacterium was isolated again in 1991 at the RAF Institute of Pathology and 
Tropical Medicine, Halton, Aylesbury, from a patient with neurotropic cornea 
(Hall et al., 2001, pp. 1202-1203).  A full phenotypic and phylogenetic 
characterization of the organism, using 16S rRNA DNA sequencing studies, was 
then carried out at the Department of Microbiology, Agriculture and Food 
Research Council, Reading.  Phylogenetically the organism was closest in 
affinity to Aerococcus and Globicatella but, being genealogically distinct, was 
classified in a new genus, Dolosigranulum, of which it is the sole species 
(Aguirre et al., 1993, pp. 608-612). The original isolate from Colchester was 
deposited as the type strain at the National Collection of Industrial, Marine and 
Food Bacteria, Aberdeen (NCIMB 702975).  It was named D.   pigrum 
gen.nov.,sp nov. (Aguirre et al., 1993, pp. 608-612) by Professor Ozro MacAdoo 
at Virginia Polytechnic and State University, Blacksberg, Virginia, USA, 
(dolosus, Latin, crafty, deceitful; granulum a small grain, pigrum, Latin, lazy).  
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As the name suggests D.  pigrum can be difficult to culture and detect due to the 
long incubation time and the initially small colonies it forms.  It grows more 
readily on solid medium than in liquid culture, but liquid culture is possible using 
„brain heart infusion‟ broth.  Further studies have confirmed that the organism is 
catalase negative and although initially it demonstrates  haemolysis, incubation 
for more than a week at either 37°C or at room temperature or prolonged storage 
at 4°C, results in  haemolysis.  It is possible, therefore, that D.  pigrum produces 
 haemolysins as stress protein if growth is inhibited or restricted, but this 
remains to be investigated.  The initial 16S rRNA sequencing yielded the D. 
pigrum gene sequence from the type strain (acc. X70907).  By the beginning of 
the next century it was apparent that the bacterium was a significant pathogen 
with isolates being reported in specimens such as blood cultures and eye 
specimens (Table 1.1, LaClaire & Facklam, 2000a, pp. 2001-2003). Since then it 
has been implicated in a number of infections (section 1.3.5). 
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Table 1.1.  Sources, clinical diagnoses, and demographic information on 
27 strains of Dolosigranulum pigrum (LaClaire & Facklam, 2000). 
 
 
 
 
 
1.4.3 Production of anti-Dolosigranulum  pigrum in rabbits 
After its identification as a novel species, further investigation of the organism 
was performed by producing antibody to it using four rabbits (R3-R6).  The 
rabbit antisera (R3,R4, R5 and R6) employed in this study were the gift of 
Professor G.W.A. Dick. The antisera were prepared by Professor Dick at the 
animal unit of the University of Surrey.  Immunizations and all related 
procedures were carried out under the relevant Home Office regulations (circa 
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1987).  The resulting D.  pigrum antisera were initially employed in a study of 
the antigenic relationship of D.  pigrum to biochemically similar species and the 
results were published by Aguirre and co-workers (Aguirre et al., 1993, pp. 608-
612).  The methods employed appear in Appendix E. 
These four rabbit antisera formed the basis of further work into the possible 
identity of bacterial antigen(s) detected in early acute MS CNS tissue.  All rabbit 
antisera to D.  pigrum were screened for antibody to Brain Heart Infusion 
medium (BHI) using BHI on 12% polyacrylamide gels followed by Western 
blotting, as described in 2.7 and no antibodies were detected.  Similarly, human 
control and MS control sera had no detectable antibody to BHI using these 
techniques (D. Gay, personal communication, January 16, 2014). 
 
1.4.4 Experiments using rabbit antisera 
Investigations using the rabbit antisera R3, R4, R5 and R6 were begun.  Cryostat 
sections of the frozen spinal cord tissue from which D. pigrum was isolated were 
treated with R3 anti-D.  pigrum serum at a titre of 1/100, and stained using 
biotinylated goat anti-rabbit, streptavidin-horse radish peroxidase and colour 
development with 3,3′-diaminobenzadine tetrahydrochloride (DAB). Positive 
reactions with an antigen („R3.89‟) were found throughout these tissues (Figure 
1.9), with the strongest and most frequent being within activated macrophages in 
the meninges, in the perivascular (Virchow-Robin) spaces and in the microglia. 
The pre-immune serum showed no reaction, and no reaction was found when a 
wide range of neurological tissue from normal control brain tissues and a variety 
of other neurological diseases were tested. However, similar positive reactions 
were found in other MS tissues, but all were from early stages of the disease (D. 
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Gay, personal communication, December 22, 2008).    All of the four rabbit 
antisera were subsequently tested and it was seen that R3 reacted most strongly, 
producing a signal at 1/100 dilution. R4 produced a positive reaction in the 
tissues at 1/10 dilution, R6 in 1/5 dilution and R5 at less than a 1/5 dilution. 
 
 
Figure 1.9. Cryostat section of spinal cord which grew Dolosigranulum pigrum 
showing R3.89 antigen (arrowed) in cytoplasmic vesicles. Treated with rabbit 3 
anti-D. pigrum serum at 1/100, and stained using biotinylated goat anti-rabbit 
and streptavidin-horse radish peroxidase. Colour development 3,3′-
diaminobenzadine tetrahydrochloride (DAB). Positive reactions (antigen R3.89) 
were found throughout these tissues, the strongest and most frequent within 
activated macrophages within the meninges, in the perivascular spaces, and in 
microglia (Figure provided by Dr. F. W. Gay). 
 
This immuno-histological observation using rabbit antisera led to a postulation 
that the antigen(s) in MS tissue were in fact small transportable (extracellular) 
bacterial proteins, possibly produced by D. pigrum, that might be a causative 
factor in the development of MS plaques.  The idea of identifying the tissue 
antigen(s) by relative reactivity was the subject of an undergraduate thesis by 
C.W. Gay (2007).  In these investigations the small transportable protein antigens 
of D. pigrum were investigated, using SDS-PAGE and Western blotting 
techniques (Figure 1.10).  The investigations used the four rabbit antisera (R3, 
R4, R5, R6) to D. pigrum to detect D. pigrum peptides and the possible identity 
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and pathogenicity of these peptides was discussed.  The study defined up to ten 
distinct small peptides (denatured) that all mirrored the characteristic tissue 
reactivity to the different D .  pigrum rabbit antisera. 
 
 
Figure 1.10. Western blot of an extracellular (no cells) preparation 
of Dolosigranulum pigrum reacted against rabbit 3, 4, 5 and 6 anti-
Dolosigranulum pigrum antibody, with a pre-immune rabbit negative control (P) 
from R3.  All the other rabbit pre-immune sera (R4-6) also showed a lack of 
bands.  This Western blot illustrates the comparative band strength produced by 
the four rabbit antisera. It also illustrates the range of low molecular weight 
bands. (C. Gay, 2007). 
 
 
 
1.4.5 Epidemiology of Dolosigranulum pigrum 
The ability of D.  pigrum to survive in inhospitable conditions was demonstrated 
by 16S rRNA detection of it among Staphylococcus species, Moraxella species 
and other bacteria, in clean rooms where spacecraft are assembled at three 
separate centres in America (Moissl et al., 2007, pp. 509-521). 
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 The pathogenic potential and worldwide occurrence of D.  pigrum has recently 
been highlighted in several reports (Table 1.2).  In China it has been implicated 
in a case of acute cholecystitis accompanied by acute pancreatitis (Lin et al., 
2006, pp. 2298-2299) and has been found in a case of synovitis in the USA (Hall 
et al., 2001, pp. 1202-1203) and septic arthritis in Norway (Johnsen, Rønning, 
Onken, Figved & Jenum, 2011, pp. 85-87), whilst in the Netherlands it has been 
isolated from a case of ventilator associated pneumonia (Hoedemaekers, Schulin, 
Tonk, Melchers & Sturm, 2006, pp. 3461-3462), and in France it was found in a 
case of non-ventilator associated pneumonia and septicaemia (Lécuyer et al., 
2007, pp. 3474-3475).  In these studies, and in a review article by LaClaire and 
Facklam (2000a, pp. 2001-2003), the organism was found to be susceptible to 
most commonly used antibiotics, with the exception of erythromycin.  Reduced 
susceptibility to chloramphenicol and trimethoprim-sulfamethoxazole was 
detected in some strains. D.  pigrum was also discovered in the sputum of cystic 
fibrosis patients by Bittar and co-workers (Bittar et al., 2008) using PCR and 
cloning of the the purified PCR products (Table 1.2). Their finding of eight 
clones of the bacterium amongst a total of 392 clones of 55 other bacterial 
species illustrate the complexity and diversity of the flora found in the disease.  
The authors concluded that in conjunction with other bacteria, D.  pigrum could 
be a cause of pulmonary infections in cystic fibrosis. These findings were 
corroborated by a later study (Armougom et al., 2009, pp. 1151-1154).  
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Table 1.2.  Reported clinical isolates of Dolosigranulum pigrum since LaClaire 
& Facklam‟s (2000) study showing diagnosis and geography. 
 
Date Source Clinical diagnosis Locale 
2001 Blood culture Synovitis/sepsis USA 
 
2006 Blood culture Cholecystitis/pancreatitis China 
 
2006 Bronchial 
secretions 
Pnemonia Netherlands 
 
 
2007 Broncho- 
alveolar lavage 
Pneumonia France 
 
 
2008 Sputum Cystic fibrosis France 
 
2009 Sputum Cystic fibrosis Germany 
 
2011 Synovial biopsy Septic arthritis Norway 
 
 
 
1.4.6 Association of Dolosigranulum pigrum with multiple 
sclerosis 
 
As already stated, antibodies to D.  pigrum low molecular weight antigens have 
been found to react with an immune complex in very early pre-demyelinating 
lesions in MS tissues (Figure 1.7).  This research project aimed to look at the 
potential relationship of D.  pigrum with MS by measuring antibodies to D.  
pigrum in MS cases and in matched controls.  If leakage of bacterial products 
into the CNS occurs via the posterior sinuses in MS then it was important to 
confirm that the upper respiratory tract is the natural habitat of D.  pigrum.  
When this study commenced in 2006 there was speculation that D.  pigrum was 
part of the normal flora of the nasal cavity and the naso-pharynx (LaClaire & 
Facklam, 2000a, pp. 2001-2003).  Recently evidence has been found that 
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suggests this is the case (Cho, Jung, Kim & Chang, 2011, pp. 18-22) and may 
play a protective role in colonization resistance against potential upper 
respiratory tract pathogens such as Streptococcus pneumoniae and Haemophilus 
influenzae (Laufer et al, 2011, pp. 1-6).  Additionally, Bogaert et al. (2011, para. 
1- 8) found evidence of seasonal variation in the microbial flora of children with 
an increase in bacterial numbers and diversity of both potential pathogens and 
normal flora, including D.  pigrum in the autumn and winter.  These findings 
correlate with seasonal increases in respiratory infections,(White et al., 2009, p. 
196; Kinlan et al., 2009, pp. 588-595), sinusitis and MS (Gay, 1991). 
 
1.5 Aims and objectives of the study 
 
Aims 
The bacterial toxins hypothesis in MS postulates that bacterial transportable 
toxins generated by the flora of the human nasopharynx access the central 
nervous system and are implicated in the pathogenesis of the disease.  
The bacterium D.  pigrum was originally isolated from and first identified in 
acute multiple sclerosis tissues. The aims of this study were:  
1) Determine if the organism is a normal inhabitant of the nasopharyngeal 
flora in man (Figure 2.1). 
2) To explore the relationship between D.  pigrum infection and MS (Figure 
2.2). 
Objectives 
 To design and use an enzyme linked immunosorbant assay to screen for 
antibody (IgG) to D.  pigrum in the serum of MS patients and a control group. 
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 To characterize, using Western blotting, any antibodies found in the enzyme 
linked immunosorbant assay and establish any points of similarity between them 
by comparison of their electrophoretic banding pattern. 
 To screen for D.  pigrum in nasal and other specimens using bacteriological 
cultural techniques.   
 To develop and use primers to D.  pigrum and set up a polymerase chain 
reaction test to screen for the presence of the bacteria in nasal and other 
specimens sent for microbiological culture. 
 To use the results from this project to test the bacterial toxins hypothesis of MS 
and assess the feasibility of using the ELISA and Western blotting tests used for 
this project to develop specific diagnostic tests for MS, enabling early diagnosis 
and treatment of the disease before serious damage occurs to the brain and 
spinal cord. 
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Chapter 2:                                                   
Methods 
 
2.1 Flow charts showing methodology for the 
two aims of the project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Project aim 1. 
To determine if the organism is a normal inhabitant of the nasopharyngeal flora in 
man using eighty eight anonymised residual swab samples and various body fluids 
from Colchester microbiology 
 
 
 
88 anonymised, residual samples  
(swabs and fluids) 
Bacterial culture 
Negative control 
S.pnemoniae ATCC 
49619 
Positive control D. 
pigrum NCIMB 
702975 
 
DNA extraction (Invitrogen) 
PCR 
16SrRNA X70907 
Positive control 
NCIMB 702975 
30/88 positive 
Gram stain 
FITC 
Gene sequencing 
12 positive 
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Figure 2.2. Project aim 2. 
To explore the relationship between Dolosigranulum pigrum infection and multiple 
sclerosis  by measuring antibody to the bacterium in multiple sclerosis patients and 
in matched controls using sixty five anonymised residual sera from confirmed cases 
of multiple sclerosis from the  Neurology Unit, Queens Square, London and sixty 
five anonymised residual sera from age and sex matched controls from Colchester 
microbiology 
 
 
 
 
 
 
R6 rabbit anti-
D.pigrum sera 
Pre-immune rabbit sera 
Anonymised residual sera 
65 confirmed MS 
65 sex and aged matched 
controls (ANC and well 
patient clinics) 
 
ELISA 
Anti-rabbit IgG 
peroxidase 
Triturus 
ELISA 
analyser 
ELISA 
R6 / preimmune controls 
with Anti-rabbit IgG 
peroxidase 
 
ELISA 
65 MS and 65 sex and age 
matched sera (and pos and 
neg controls) run in 
triplicate 
ELISA 
16 random MS and 
matched controls run to 
get a high and low 
reference samples using 
anti-human IgG 
peroxidase 
 
Western blotting 
15 high OD MS and 
matched controls 
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2.2 Specimens used for the project 
 
2.2.1 Ethical approval 
Approval for this project was granted by the National Research Ethics Service 
(NRES) and the Research and Development Department of the Colchester 
Hospital University Foundation Trust (Appendix A1). 
 
2.2.2 Specimens used for culture, fluorescence microscopy and 
polymerase chain reaction  
 
Eighty eight anonymised residual samples (respiratory, eye and ear swabs (in 
Amies transport media) and various body fluids) sent for diagnostic testing to the 
Microbiology Department, Colchester Hospital University Foundation Trust, 
were used for this project. The specimens were collected in September and 
October 2008 after routine microbiological testing and kept frozen at -20°C, as 
were cultures of Dolosigranulum  pigrum NCIMB 702975.  These were 
inoculated into Amies transport media, pending bacterial culturing for 
Dolosigranulum pigrum, fluorescence microscopy, Western blotting (WB) and 
PCR.   Dolosigranulum  pigrum NCIMB 702975 survival was checked before 
culture.  Microscopy was begun and was found to be satisfactory.  
 
 2.2.3 Specimens used for enzyme linked immunosorbent assay 
and Western blotting 
 
Test group: Sixty five anonymised residual sera from confirmed cases of MS 
from the Institute of Neurology, National Hospital for Neurology and 
Neurosurgery, Queen Square, London WC1N 3BG.  Specimens were kept frozen 
at –20°C until required. 
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Control group: Sixty five anonymised residual sera from routine ante-natal 
testing, and well-patient testing from the Serology Department, Microbiology 
Department, Colchester Hospital University Foundation Trust. These were age 
and sex matched to the test group, and the sera were kept frozen at –20°C. 
 
2.3 Culture for Dolosigranulum pigrum 
All the specimens were cultured onto Columbia agar (Oxoid CMO331) with 5% 
horse blood (TCS Biosciences, HBO34) added (BA).  The plates were incubated 
for 7 days in 5% CO2 at 37°C.   Tiny α haemolytic colonies were sub-cultured 
onto BA purity plates and incubated as before.  If Gram staining revealed Gram 
positive cocci (see Figure 3.4b) then the presence of D.  pigrum was tested for 
using R3 (see 1.4.3 Production of anti-D.  pigrum in rabbits) and FITC-labelled 
goat anti-rabbit IgG (Sigma, F1262), using D.  pigrum NCIMB 702975 as a 
positive control, and Streptococcus pneumoniae ATCC 49619 as a negative 
control. The controls and tests were made by inoculating 2 ml of phosphate 
buffered saline (PBS) (BBL FTA haemagglutination buffer, phosphate buffered 
saline pH 7.2 +/- 0.1, Becton Dickinson 211248) with harvested cultures from 
Columbia blood agar plates, and adjusting the suspension so that the optical 
densities equated to a McFarland 2 standard.  The suspensions were then 
centrifuged at 120 × g for 10 min and the pellet washed once in PBS and re-
suspended in 1 ml of PBS before being cultured onto Columbia blood agar plates 
to check that were no losses to controls or test organisms. 
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2.4 Fluorescein isothiocyanate method to 
detect Dolosigranulum pigrum 
 
 
One 10 l loop of well mixed test or control suspension was then emulsified in 
25 l of PBS on a glass slide and left to air dry before fixing with acetone, which 
was left until the acetone evaporated.  
The rabbit antisera (R3) was stored at -20°C undiluted.  Twenty five l of a 1/50 
dilution of R3 in PBS was added to each fixed preparation on a slide and 
incubated in a damp chamber at room temperature for 30 min.  Following 
incubation, the slides were washed with PBS and blotted dry.  Twenty five l of 
a 1/50 dilution of FITC-labelled goat anti-rabbit conjugate (Sigma, F1262) in 
PBS was then added and the slides left in the dark in a damp chamber for 30 min 
at room temperature.  The slides were then washed with PBS and blotted dry.  
After mounting with Detect IF mountant (Axis-Shield) the slides were examined 
for fluorescence using an ultra violet microscope with a 450-480 nm excitation 
500 nm emission filter. 
 
2.5 DNA extraction method 
PureLink Genomic DNA kits from Invitrogen (K1820-01) were used for all 
extractions (see Appendix B.1).   
2.5.1 Preparation of naso-pharyngeal aspirates, mucous and 
swabs 
 
Naso-pharyngeal aspirates (whole samples) were centrifuged at 9000 × g for 9 
min and the pellet used for DNA extraction. 
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Approximately 10 ml of mucous was combined with 180 μl of PureLink 
Genomic Digestion Buffer and 20 μl of 20 μg ml-1 PureLink Proteinase K and 
incubated at 55°C.  The mixture was then shaken occasionally, until the mucous 
was digested. The sample was then centrifuged at 9000 × g for 9 min and the 
pellet used for DNA extraction. 
The tip of the specimen swabs was aseptically cut off and placed directly into the 
PureLink Genomic Lysis/Binding Buffer /Lysozyme mixture, and the sample 
was then used for DNA extraction. 
 
2.5.2 DNA extraction 
Lysozyme (Sigma, L6876) was added to 300 μl of PureLink Genomic 
Lysis/Binding Buffer to obtain a concentration of 20 mg ml
-1
.  This mixture was 
then vortex mixed for 5 s.  The specimens (as prepared in 2.4.1) were then added 
and the mixture incubated at 37°C for 1 h.  After incubation, 20 μl of proteinase 
K and 200 μl of genomic lysis/binding buffer were added and then vortex mixed 
for 5 s.  The sample was then incubated at 55°C for 1 h.  If swabs were used 
these were now removed using aseptic techniques, squeezing them against the 
side of the tube to ensure that as much material as possible was extracted.  Two 
hundred μl of 100% v/v ethanol was added and the mixture was vortex mixed for 
5 s, before all the fluid was removed from the tube and added to a microfuge tube 
with a PureLink spin column.  During the development of the PCR test it was 
found that even though the amount of ethanol in the final eluted product was 
miniscule it was interfering with the PCR.  Centrifugation of open microfuge 
tubes after the ethanol had been removed, and leaving the spin columns to sit at 
room temperature for half an hour after the elution, significantly reduced ethanol 
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contamination and did not result in DNA contamination (C. Gay and McGenity, 
personal communication March 2009).  
The microfuge tube was centrifuged at 10000 × g for 1 min.  The tube was then 
discarded and the spin column transferred to a new microfuge tube.  Five 
hundred μl of PureLink wash buffer 1 was then added and the open tube 
centrifuged at 10000 × g for 1 min.   The tube was then discarded and the spin 
column placed into a new microfuge tube.  500 μl of PureLink wash buffer 2 was 
added and the open tube centrifuged at 13000 × g for 5 min.  The spin column 
was then placed into a fresh microfuge tube which was left open at room 
temperature in a fume cupboard for 30 min.  At the end of this time 25 μl 
PureLink elution buffer was added and the tube was then left open at room 
temperature in a fume cupboard for 15 min.  The tube was then closed and 
centrifuged at 13000 × g for 1 min.  The spin column was then discarded and the 
DNA extract kept frozen at -20°C. 
 
2.6 Polymerase chain reaction method 
2.6.1 Primers 
 
The primers and PCR methods were designed and developed by C.W. Gay and 
T. McGenity as part of a MSc project (Gay, 2009).  Four sets of primers were 
developed from 16S rRNA (acc. X70907) of D.  pigrum (Figure 2.1).    
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Figure 2.3. Location of primers used in the investigation of Dolosigranulum 
pigrum 16S rRNA gene (X70907).  
Primer set ‘a’: Location 166F and 1251R 
Primer set ‘b’: 165F and 1270R 
Primer set ‘c’: 226F and 1243R 
Primer set ‘d’: 447F and 747R 
 F = Forward, R = Reverse.   
 
Primer set „a‟ gave the best results and was therefore used for this project.  
Amplicons of this primer were 1085 base pairs (Gay, 2009). 
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2.6.2 Master mix formulation  
Fifty l of reactions contained 1 l of each primer made up to 10 pmol ml-1 each, 
5 l of 1mM (total) deoxynucleotide triphospates, 1l of 2.5 U Taq polymerase 
and  5 l of the PCR buffer (Qiagen), and 2 l of the template DNA.  
Amplification was performed in Gene Amp PCR system 97000 thermal cyclers 
(Applied Biosystems) as follows: 94°C for 5 min, 35 cycles of 94°C for 1 min, 
58°C for 1 min and 72°C for 2 min, with a final elongation step of  72°C for 7 
min and a holding temperature of 4°C.  Amplification of the target DNA was 
confirmed by agarose gel electrophoresis (1% w/v in TAE buffer at 100 V) and 
ethidium bromide staining. 
During the development of the primer it was demonstrated that a slightly higher 
annealing temperature of 58°C did not affect the sensitivity of the reaction so this 
was used in the hope of improving specificity.  
 
2.6.3 Electrophoretic separation of polymerase chain reaction 
products 
One % agarose gels in 1% TAE (Appendix B.2) were used for separating PCR 
products, by electrophoresis. PCR product (5 l) was combined with loading dye 
(1 l) (Appendix B.2) and the mixture added to the gel.  Five l of DNA ladder 
(Appendix B.3) was added in a separate lane. 
A 0.7% agarose gel to visualise DNA was performed on some extracted samples 
and demonstrated that DNA was being sucessfully extracted.   
 
 
  52 
 
Development of gels  
The gels were treated with ethidium bromide (0.5 g ml-1) for 20 min and then 
soaked in tap water for 20 min.  They were then examined under UV light (254 
nm) (Bio-Rad Chem Doc System). 
 
2.6.4 Purification of products for sequencing 
Twelve positive samples (bands formed at 1085 bp, or 1085 bp and 1000bp) 
were selected for sequencing (Table 3.2).  The PCR products were purified using 
QIA Quick PCR Purification Kit (Qiagen).  Three μl of the purified PCR product 
was then run in a 1% agarose gel at 100 mV for 40 min to check that sufficient 
PCR product was present.  The products were then sent for sequence analysis to 
Gene Service, 2 Cambridge Science Park, Milton Road, Cambridge CB4 0FE, 
for sequencing (Table 3.2). 
The results from Gene Service were analysed firstly using the internet tool 
Bioedit (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) which is a sequence 
alignment editor.  Sequences were analysed and if they were of interest (showing 
variable bases) they were copied into Notepad (Microsoft) and then analysed 
using BLAST (Basic Alignment Tool) (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
Results were then sent as FASTA sequence codes to CLUSTALW2 multiple 
sequence alignment  programme 
http://www.ebi.ac.uk/Tools/clustalw2/index.html). 
 
 
  53 
2.7 Development of an enzyme linked 
immunosorbent assay method for testing for 
Dolosigranulum pigrum antibody in serum 
 
2.7.1 Preparation of microtitre trays  
Preliminary studies by Dr. Bruce Roser‟s team at Cambridge Biostability, had 
shown that the production of an ELISA method to look for antibodies to 
Dolosigranulum pigrum were practical (D. Gay, personal communication, March 
2009).  These studies used a 1/5 dilution of a 5 day culture of D.  pigrum in brain 
heart infusion broth and Rabbit 6 anti-D.  pigrum pre and post immune serum.  It 
was decided to expand upon this to produce an ELISA to screen MS and matched 
controls from human sera for antibody to D.  pigrum. 
A culture of D.  pigrum National Collection of  Industrial, Food and Marine 
Bacteria  (NCIMB) 702975 was inoculated into 200 ml of brain heart infusion 
broth and incubated with shaking at 50 rpm at 37°C for 5 days.  This was used as 
a stock solution and was stored at -20°C.  The culture was demonstrated to be 
both viable and pure by sub-culturing onto a blood agar plate and incubating at 
37°C for 5 days.  The stock solution from the 5 day culture was then centrifuged 
at 1000 × g for 20 min and the supernatant taken off.  The supernatant was 
diluted 1 in 5 with PBS and 200 µl was pipetted into each well of a 96 well 
microtitre tray (Sterilin 611 F96) and left overnight at 4°C.  The wells were then 
washed five times using a Triturus ELISA analyser and then 350 µl of a 1% 
solution (in PBS) of a blocking agent, chicken egg albumin (Sigma A5503), was 
added to each well (reagents and materials, Appendix B4).  The tray was left 
overnight at 4°C and then washed five times in PBS using the Triturus. 
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2.7.2 Establishing a methodology for an enzyme linked 
immunosorbent assay test for anti-Dolosigranulum pigrum 
 
Previous work had led to the development of D.   pigrum antibodies in rabbits.  
All rabbits, R3-R6, were found to be hyper-immune to D.  pigrum  with visual 
bands on Western blotting.  The fluorescent antibody titres of R6 were found to 
be 1/250,000 and therefore suitable for the ELISA investigations (D. Gay, 
personal communication, December, 2008) and was used as a positive control.  
The pre-immune serum from this animal was used as the negative control. 
Preliminary investigations conducted by Cambridge Biostability (D. Gay, 
personal communication, December, 2008) had indicated that a 1/100 serum 
dilution in PBS with a 1/10,000 dilution of anti-rabbit IgG peroxidase conjugate 
in PBS were the optimum concentrations for establishing an ELISA test for 
screening for anti-D.  pigrum.  A range of titrations using R6 and R6 pre-immune 
rabbit sera as positive and negative controls respectively showed that a 1/100 
serum dilution and 1/16,000 dilution of anti-rabbit IgG peroxidase conjugate was 
the ideal concentration (Table 2.1) .   
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Table 2.1 Titration of R6 and anti-rabbit IgG peroxidase conjugate to find the 
ideal concentrations. 
Dolosigranulum pigrum (NCIMB 702975) supernatant from a 5 day culture was 
diluted 1 in 5 with PBS and 200 µl was pipetted into each well of the microtitre 
tray (Sterilin 611 F96) and left overnight at 4°C.  The wells were then washed 
five times and then 350 µl of a 1% solution (in PBS) of a blocking agent, chicken 
egg albumin (Sigma A5503), was added to each well (reagents and materials, 
Appendix B4).  The tray was left overnight at 4°C and then washed five times in 
PBS. Dilutions of the anti-rabbit IgG conjugate and R6 were then added along 
with 1/100 pre-immune R6 sera.  
 
                                                             R6 
 Negative 
Pre-
immune 
R6 1/100 
1/25 1/50 1/75 1/100 
1/4000 1.414 2.714 2.907 2.905 2.936 
1/8000 0.672 1.748 1.828 1.8 1.818 
1/12000 0.401 1.293 1.385 1.413 1.352 
1/16000 0.281 0.858 0.97 0.973 0.963 
      
Anti-rabbit IgG peroxidase conjugate 
 
 
 
2.7.3 Multiple sclerosis and matched control sera for 
Dolosigranulum pigrum antibody screen 
 
Sera from sixty five confirmed cases of MS were age and sex matched with 
asymptomatic control sera and then coded by Stephen Ball, the senior 
Biomedical Scientist in the serology department of Colchester microbiology.  All 
sera, including the positive and negative controls, were then tested „blind‟ in 
triplicate, and the samples were not decoded until after analysis. 
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2.7.4  Enzyme linked immunosorbent assay method to detect 
Dolosigranulum pigrum antibody in human sera 
 
The method  was automated using a Triturus analyzer and sixteen randomly 
selected MS and control sera were run on a plate lined with uninoculated BHI 
using the methodology in 2.6.2 and the optical densities were extremely low 
indicating that  antibodies to brain were not present (Table 2.2). Three runs using 
the same sixteen randomly selected MS and control sera and methodology were 
performed on microtitres plates lined with a 1/5 dilution of D.  pigrum in BHI 
with anti-human IgG peroxidase in conjunction with the positive and negative 
rabbit controls with anti-rabbit IgG peroxidase (Sigma A6029) to ensure that the 
method worked with human sera, and to optimize the wash cycle and incubation 
times (2.6.3).  It was shown that a 1/100 dilution of human serum and a 1/16,000 
dilution of the anti-human IgG peroxidase conjugate were optimal. Three 
samples containing PBS instead of sera were also used with a 1/16,000 dilution 
of the anti-human IgG peroxidase conjugate and gave optical densities of  0.153, 
0.240 and 0.176 respectively.  The runs were also used to find a sample with a 
high optical density that could be used as a positive reference sample (serum 
36490, see Table 3.4 ) and a sample with a low optical density that could be used 
as a negative reference sample (serum 36590, see Table 3.5).   
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Table 2.2.  Detection of antibodies to brain heart infusion in multiple sclerosis 
and control sera. 
200 µl Brain Heart Infusion broth (neat) was pipetted into each well of the 
microtitre tray (Sterilin 611 F96) and left overnight at 4°C.  The wells were then 
washed five times and then 350 µl of a 1% solution (in PBS) of a blocking agent, 
chicken egg albumin (Sigma A5503), was added to each well (reagents and 
materials, Appendix B4).  The tray was left overnight at 4°C and then washed 
five times in PBS before 1/100 MS and control sera were added. 1/16,000 
dilution of 100 μl anti-human IgG peroxidase conjugate and 
tetramethylbenzadine buffer/chromagen added with a stopping solution of 
sulphuric acid. 
 
MS 
ID 
OD  Control 
ID 
OD 
36452 0.052  36475 0.063 
36455 0.059  36478 0.071 
36461 0.063  36505 0.073 
36483 0.057  36507 0.082 
36487 0.062  36510 0.082 
36490 0.066  36512 0.063 
36494 0.071  36541 0.054 
36497 0.075  36543 0.058 
36498 0.071  36546 0.038 
36516 0.065  36570 0.045 
36519 0.056  36572 0.045 
36526 0.050  36586 0.062 
36529 0.067  36590 0.070 
36550 0.078  36595 0.070 
36555 0.077  36601 0.056 
36561 0.075  36604 0.051 
 
Using prepared microtitre trays (see 2.6.1).  The sera were diluted 1/100 and 100 
μl was added to each microtitre well.  The plate was then incubated at 37°C for 1 
h, and the wells washed  five times using 350 l per well (30 s soak) with PBS.  
A 1/16,000 dilution of 100 μl anti-human IgG (whole molecule) peroxidase 
conjugate (Sigma A6029) was added, and the microtitre plate incubated at 37°C 
for 30 min (stationary).  The plates were then washed five times again, using 350 
l per well (30 s soak) with PBS.   
One hundred l tetramethylbenzadine buffer/chromagen (TMB) (BioRad 
492430) was added to each well, and the microtitre plate incubated at room 
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temperature for 30 min.  One hundred l stopping solution (1 N sulphuric acid) 
was then added to each well, and the plate read on the Triturus using a read filter 
of 450 nm and a reference filter of 620 nm.   
 
 
2.8 Western blotting 
Fifteen of the MS sera demonstrating high optical density in the D.  pigrum 
ELISA along with their age and sex matched controls were tested using Western 
Blotting. 
 
2.8.1 Gel preparation    
The gel was produced between two glass plates using the clamping system of the 
Mini-Protean II slab cell (BIO-RAD).  A spacer thickness for the casting plates 
of 0.75 mm was used which employed a total of 4.2 ml of gel monomer.  The gel 
used was a discontinuous (Laemmli) gel consisting of a 4% stacking gel which 
concentrated the sample to give better band resolution, and a 12% separating gel 
which facilitates separation of the molecules. The separating gel monomers were 
prepared by adding all the ingredients except ammonium persulphate and 
tetramethylethylenediamine (TEMED).  These were de-aerated using a vacuum 
pump for 15 min.  The ammonium persulphate and TEMED were then added and 
mixed. A comb was placed into the gel sandwich.  A mark of 1 cm was drawn 
from the top of the casting plate and the separating gel was delivered up to this 
mark using a pipette, taking care not to mix the solution with air.  The gel was 
then overlayed carefully with distilled water and left to polymerize for 1 h.   
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The ingredients for the stacking gel were then combined except ammonium 
persulphate and TEMED (reagents and materials Appendix B5).  The gel was de-
aerated using a vacuum pump for 15 min.  The ammonium persulphate and 
TEMED were then mixed in.  The water above the separating gel was taken off 
and dried with blotting paper before the stacking gel was poured.  This was then 
left to polymerize for 1 h.  The gel sandwiches and clamp assembly were then 
removed from the casting stand and attached to the cooling core.    A 1/5 dilution 
of the stock electrode buffer was then made with distilled water to 300 ml.  The 
inner cooling core was lowered into the lower buffer chamber and 115 ml of 
buffer was added to the upper buffer chamber so that it reached a level halfway 
between the two glass plates of the gel sandwich.  The remainder of the electrode 
buffer was then poured into the lower buffer chamber so that at least the bottom 
1 cm of the gel was covered.  Any air bubbles formed at the bottom of the gel 
were carefully removed to ensure good electrical contact.    
 
2.8.2 Electrophoresis and Western blotting 
These studies used the supernatant of the 5 day culture of D.  pigrum (NCIMB 
702975) in brain heart infusion (as used in the ELISA part of the project).   A 1/3 
dilution of the D. pigrum supernatant in sample buffer (reagents and materials, 
Appendix B6) was heated to 98°C for 4 min.  After cooling, 400 l was added to 
the stacking gel under the electrode buffer.  The cooling clamp was then removed 
and the lid of the top of the buffer chamber was closed to fully enclose the cell.  
The electrical leads were connected and the electrophoresis was run at 140 V for 
1 h.   After electrophoresis, the gel was removed and placed in equilibration 
buffer (Tris 3.03 g, glycine 14.4 g, de-ionised water, methanol v/v 200 ml, pH 
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8.3 ued at 4 °C) for 15 min to remove buffer salts and detergents.  The 
nitrocellulose membrane was cut to the size of the gel and orientation of the 
membrane was identified by nicking  the top left edge.  Using forceps, the 
membrane was slowly added at an angle of 45° to the transfer buffer and allowed 
to soak for 15 min.  The pre-cut filter paper and fibre pads were soaked in 
transfer buffer, and the buffer tank half filled with transfer buffer . (Tris 3.03 g, 
glycine 14.4 g, de-ionised water, methanol v/v 200 ml, pH 8.3 ued at 4 °C).  The 
cooling unit was installed in the buffer chamber next to the electrodes.  The gel 
holder cassette was assembled, and the gel and membrane inserted according to 
the manafacturer‟s instructions. The Western blot was then run at 100 V for 1 h.  
After this time the membrane was washed with PBS and blocked with 2% 
milk/PBS for 30 min.  The membrane was then cut into strips and stored at 4°C 
in 0.2% milk/saline for 12 h.   
For immunoprobing each strip was then placed in a sterile universal bottle and 
0.5 ml of MS or matched control sera was added. The bottles were then placed 
on a roller and mixed for 1 h.  Two runs were performed using the following 
sera. 
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Table 2.3. Multiple sclerosis and matched control sera used for Western blotting 
using the BioRad Mini-Protean. 
 
 
Run1  Run 2 
MS sera Matched 
control sera 
 MS sera Matched 
control sera 
036563 036603  36548 36574 
036528 036587  36524 36660 
036454 036597  36529 36506 
036455 036601  36521 36572 
036456 036475  36464 36584 
036460 036541  36484 36570 
   36494 36576 
   36488 36505 
   36496 36478 
     
 
 
 
After rolling the sera were discarded and the strips washed in 20 ml of 0.2% 
milk/PBS three times.  0.5 ml of the second antibody goat anti-human IgG at 
1/1000 dilution was added and the strip rolled for 1 h.  The strip was washed 
three times with 0.2% milk/PBS and then 0.5 ml of a 1/1000 dilution of anti-goat 
IgG labelled with horse radish peroxidase (Appendix B5) was added and rolled 
for 1 h.  The strips were then washed three times with distilled water and then 
reacted with diaminobenzidine (DAB) colour reagent (Sigma D6815) for 30 min.  
The strips were then washed three times with distilled water, air dried and 
mounted.  
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Chapter 3:                                                  
Results 
 
 
3.1 Samples tested by culture, fluorescein isothiocyanate  and 
polymerase chain reaction for Dolosigranulum pigrum 
 
Eighty eight samples were tested as shown in Table 3.1.  They ranged from 
newborn to 78 years old, and 47 (53.4%) were male and 41 (46.6%) were female. 
 
 
3.1.1 Fluorescein isothiocyanate and culture results for Dolosigranulum 
pigrum 
 
To test for the presence of D.  pigrum by fluorescein isothiocyanate (FITC) 
(Figure 3.4a), 88 swabs and fluids sent for diagnostic testing to the Microbiology 
Department, Colchester Hospital University Foundation Trust, were cultured for 
D.  pigrum on blood agar plates along with D.  pigrum NCIMB 702975 (Figures 
3.1, 3.2, 3.3, 3.4b) which was used as a positive control and S.  pneumoniae 
ATCC 49619 which was used as a negative control.  Microbiological results for 
pathogen screening prior to this study were also recorded (Table 3.1).  In this 
study there were 22 samples that grew colonies that resembling D.  pigrum 
NCIMB 702975 which were Gram positive cocci  (19 throat swabs, 1 nose swab, 
1 quinsy pus and 1 naso-pharyngeal aspirate (NPA) but all tested FITC- negative 
for the organism.  Twenty one were from mixed cultures and the FITC test was 
repeated taking a sweep of the mixed growth which also proved negative for D.  
pigrum.  Finally, all 88 samples were tested by directly inoculating the samples 
onto the slide and testing with FITC.  Again, all were negative for D.  pigrum 
using the FITC test. 
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Figure 3.1. Dolosigranulum pigrum NCIMB 702975 on blood agar after 72 h 
incubation at 37°C in 5%  CO2. Tiny non-haemolytic colonies of less than 0.5 
mm in diameter. 
 
 
Figure 3.2 Dolosigranulum pigrum NCIMB 702975 on blood agar after 5 days 
incubation at 37°C in 5%  CO2. Backlit plate to demonstrate α haemolytic colonies 
of 1 mm in diameter. 
 
 
  64 
 
Figure 3.3. Dolosigranulum pigrum NCIMB 702975 on blood agar after 5 days 
incubation at 37°C in 5%  CO2. Top lit plate showing white colonies of 1 mm in 
diameter.  Tiny colonies of less than 1mm (arrowed) were routinely seen on 
culture but reverted to normal colonies when subcultured. 
 
 
 
Figure 3.4. Microscopy from Dolosigranulum pigrum NCIMB 702975 on blood 
agar after 5 days incubation at 37 °C in CO2.  
(a). Dolosigranulum pigrum NCIMB 702975 stained with anti-rabbit FITC showing 
fluorescence, using rabbit anti-Dolosigranulum pigrum antibody (R3). 
(b). Gram stain of Dolosigranulum pigrum NCIMB 702975 demonstrating the 
characteristic short chains and clusters of 1– 1.5 μm Gram positive cocci. 
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3.1.2 Polymerase chain reaction results for Dolosigranulum pigrum 
 
Of the 88 samples tested (Table 3.1, Figures 3.5-3.11) 30 samples demonstrated 
bands at 1085 base pairs (34%) ranging from 8 days old to 74 years old, with 17 
of the positives being male (56.7%) and 13 being female (43.3%).  Analysis 
showed the highest percentage of D.  pigrum PCR positivity with infants (Figure 
3.12). 
Analysis of the sequencing results showed that of the twelve PCR products sent 
(Gene Service, 2 Cambridge Science Park, Milton Road, Cambridge CB4 0RE),  
three produced good signals but did not match the D.  pigrum sequence, and two 
produced mixed signals that indicated there were mixed amplicons.  The other 
seven were all good matches for D.  pigrum (Table 3.2, Table 3.3). 
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Figure 3.5. PCR run samples B1 – B6 
Agarose gel (1%) showing positive result for amplicon at 1085 base pairs with  
Dolosigranulum pigrum positive control and B6, positive results at 1085 bp with 
a second band at 1000 bp for B1 and B3, and a negative result for B2, B5 and the 
negative control. M is the marker lane with a DNA ladder. 
Gel run at 100 V, for 35 min. Stained with ethidium bromide. 
 
M    Pos    Neg C1    C2      C3    C4      C5     C6     E1      E2     E3 E4     A7     A8     A9    A10   A11    A12     B7
1085 bp
 
Figure 3.6. PCR run 141108A 
Agarose gel (1%) showing positive result for amplicon at 1085 base pairs with 
Dolosigranulum pigrum positive control (Pos) and samples C1, C3, A8 and A10 
positive result for amplicon at 1085 base pairs with a second band at 1000 bp 
with sample A12, and a negative results for all other samples and the negative 
control (Neg). M is the marker lane with a DNA ladder. 
Gel run at 100 V, for 35 minutes. Stained with ethidium bromide. 
 
 
1085 bp  
Pos   Neg     M       B1    B2      B3     B4      B5       B6 
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M B8    B9     B10   B11  B12   A13   A14   A15  A16  A17
1085 bp
 
 
Figure 3.7. PCR run 141108B 
Agarose gel (1%) showing positive result for amplicon at 1085 base pairs with 
sample B10, and a negative results for all other samples. M is the marker lane 
with a DNA ladder. 
Gel run at 100 V for 35 minutes.Stained with ethidium bromide. 
 
 
 
M   Pos  D1 D2  D3   D4  C7 Neg C8  C9  C10 C11C12 B19 B20 B21 B22 B23 B24 B25
1085 bp
 
 
 
Figure 3.8. PCR Run 181108A 
Agarose gel (1%) showing positive result for amplicon at 1085 base pairs with 
Dolosigranulum pigrum positive control (Pos) and samples C7-C12, B20, B22, 
B25, with a second band at 1000 bp with D2 and B21, and a negative result for  
all other samples and the negative control (Neg).  M is the marker lane with a 
DNA ladder. 
Gel run at 100 V for 45 minutes. Stained with ethidium bromide. 
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B26        E5           E6         E7            E8    E9           E10      Neg Pos            M   
1085 bp
 
 
 
 
Figure 3.9. PCR Run 181108B 
Agarose gel (1%) showing positive result for amplicon at 1085 base pairs with 
Dolosigranulum pigrum positive control (Pos) and samples B26,E5 and E6 , with 
a second band at 1000 bp with E9, and a negative result for  all other samples and 
the negative control (Neg).  M is the marker lane with a DNA ladder. 
Gel run at 100 V for 45 minutes.  Stained with ethidium bromide. 
 
 
 
M     Pos  Neg E10  E11  D5   D6    D7   D8   D9   D10  D11   U1   U2    U3   U4   C13  C14 C15 C16
1085 bp
 
 
 
 
 
Figure 3.10. PCR run 201108A 
Agarose gel (1%) showing positive result for amplicon at 1085 base pairs with 
Dolosigranulum pigrum positive control (Pos) and samples C13, and C15, with a 
second band at 1000 bp with U2, and a negative result for all other samples and 
the negative control (Neg). 
Gel run at 100 V for 1 h.  Stained with ethidium bromide. 
 
 
 
 
 
  69 
 
 
M      C17     C18     C19     A19      A20      A21     E13    E14     E15
1085 bp
 
 
 
Figure 3.11. PCR run 201108B 
Agarose gel (1%) showing positive result for amplicon at 1085 base pairs with 
sample A20, with a second band at over 1085 bp with C19 and with a second 
band at 1000 bp with C17, and a negative result for all other samples. 
Gel run at 100 V, 400 mA for 1 h.  Stained with ethidium bromide. 
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Table 3.1. Comparison of polymerase chain reaction results with nasal specimen 
culture results, showing patient demographics and type of specimen.  
 
 
I.D. Specimen 
type 
Sex Age PCR 
result 
for D. 
pigrum 
Position 
of band 
 Microbiology 
results prior 
to project  
A1 NS F 23 y Neg   SAU +/- 
A2 NS M 15 y Neg   SAU ++ 
A3 NS F 53 y Neg   NG 
A4 NS F 65 y Neg   NF 
A5 NS F 18 y Neg   NG 
A6 NS F 64 y Neg   SAU +/- 
A13 NS M 8 y Neg   SPN++ 
 froA14 NS M 38 y Neg   SAU+++ 
COL+++ 
A15 NS M 9 y Neg   NF 
A16 NS M 40 y Neg   +SAU 
A17 NS F 28 y Neg   +/-SAU 
A19 NS F 28 y Neg  
 
 NF 
A20 NS M 71 y + 1085 bp  MIXCOL+ 
A21 NS M 38 y Neg   SAU+/- 
NF+/- 
B7 NS F 66 y Neg   MRS+ 
B8 NS F 53 y Neg   NF 
B9 NS F 59 y Neg   SAU+/- 
B10 NS M 73 y + 1085 bp 
 
 COL+ 
NF+ 
B11 NS M 9 y Neg   HSA+ 
SAU++ 
E14 NS F 78 y Neg   NF 
D1 NMU F 57 y Neg   NF 
D2 NMU M 62 y + 1085 bp 
1000 bp 
 MOR+ 
NF++ 
D4 NMU M 2 m Neg   COL++ 
D5 NMU F 68 y Neg   NF 
D6 NMU M 64 y Neg   NF 
D9 NMU M 22 y Neg   HSA++ 
D10 NMU M 2 y Neg   NF 
 
 
Key to Table 3.1. ID = Specimen number, y = years old, m = months old,  M = Male, F = Female, 
NS = Nose swab, NMU = Nasal mucous. Culture results from routine microbiology 
investigations prior to this study: SAU = Staphylococcus aureus, SPN = Streptococcus 
pneumoniae, COL = coliform, MIXCOL = Mixed coliform, MRS = Methicilllin resistant 
Staphylococcus aureus, HAS = Streptococcus pyogenes, MOR = Moraxella species, NF = 
Normal flora, NG = No growth. 
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Table 3.1 continued. Comparison of polymerase chain reaction results with 
throat specimen culture results, showing patient demographics and type of 
specimen. 
 
 
 
I.D. Specimen 
type 
Sex Age PCR 
result 
for D. 
pigrum 
Position 
of band 
Microbiology 
results prior 
to project 
A7 TS F 19 y Neg  NF 
A8 TS F 19 y + 1085 bp 
 
HSA+ 
NF+ 
A9 TS F 24 y Neg  NF 
A10 TS M 2 y + 1085 bp 
 
NF 
A11 TS F 2 y Neg  NF 
A12 TS F 19 y + 1085 bp 
1000 bp 
NF 
B1 TS F 3 y + 1085 bp 
1000 bp 
NF 
B2 TS M 2 y Neg  NF 
B3 TS F 37 y + 1085 bp 
1000 bp 
NF 
B4 TS F 41 y Neg  NF 
B5 TS M 10 y Neg  NF 
B6 TS M 12 y + 1085 bp HSA++ 
NF++ 
B19 TS M 20 y Neg  NF 
B20 TS F 21 y + 1085 bp 
 
NF 
B21 TS M 17 y + 1085 bp 
1000 bp 
NF 
B22 TS F 7 m + 1085 bp 
 
NF 
B23 TS F 71 y Neg  CAN++ 
NF++ 
B24 TS M 22 y Neg  NF 
B25 TS M 1 y + 1085 bp 
 
NF 
B26 TS M 9 m + 1085 bp 
 
NF 
D8 TMU F 22 y Neg  HSG+ 
 
 
Key to Table 3.1. ID = Specimen number, y = years old, m = months old,  M = Male, F = Female, 
TS = Throat swab, TMU = Throat mucous. Culture results from routine microbiology 
investigations prior to this study: HAS = Streptococcus pyogenes, HSG = Haemolytic 
streptococcus group G, Can = Candida species, NF = Normal flora, NG = No growth. 
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Table 3.1 continued. Comparison of PCR results with Naso-pharyngeal aspirate 
(NPA) results, showing patient demographics. 
 
 
 
I.D. Specimen 
type 
Sex Age PCR 
result 
for D. 
pigrum 
Position 
of band 
Microbiology 
results prior 
to project 
C1 NPA M 8 m + 1085 bp RSV  
MOR + 
C2 NPA M 7 m Neg  NF 
C3 NPA M 9 m + 1085 bp SPN 
C4 NPA M 3 m Neg  COL+/- 
C5 NPA M 2 w Neg  NF 
C6 NPA F 1 m Neg  NF 
C7 NPA M 8 d + 1085 bp HIN++ 
SPN++ 
MOR++ 
NF++ 
C8 NPA M 8 m + 1085 bp NF 
C9 NPA F 1 m + 1085 bp NF 
C10 NPA M 7 m + 1085 bp NF 
C11 NPA M 2 m + 1085 bp NG 
C12 NPA F 1 y + 1085 bp NF 
C13 NPA F 2 m + 1085 bp RSV  
C14 NPA M 2 m Neg  RSV 
C15 NPA M 3 m + 1085 bp NF 
C16 NPA M 1 m Neg  MOR+ 
C17 NPA M 2 w + 1085 bp 
1000 bp 
NF 
C18 NPA M 3 m Neg  
 
NG 
C19 NPA M 10 m + 1085 bp 
^1085 bp 
SAU+ 
NF+++ 
 
 
Key to Table 3.1. ID = Specimen number, y = years old, m = months old, d = days old, w = 
Weeks old, M = Male, F = Female, NPA = Naso pharyngeal aspirate. Results from routine 
microbiology investigations prior to this study: SAU = Staphylococcus aureus, SPN = 
Streptococcus pneumoniae, COL = coliform, MOR = Moraxella species, RSV = Respiratory 
Syncytial Virus, NF = Normal flora, NG = No growth. 
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Table 3.1 continued. Comparison of PCR results with miscellaneous specimen 
culture results, showing patient demographics and type of specimen. 
 
 
 
I.D. Specimen 
type 
Sex Age PCR 
result 
for D. 
pigrum 
Position 
of band 
Microbiology 
results prior 
to project 
B12 ETH F 66 y Neg  SAU+ 
D3 QAS M 22 y Neg  SMI+ 
D7 QAS F 34 y Neg  HSA+/- 
NSA++ 
D11 AWO M 50 y Neg  SPN++ 
E1 EYE M 41 y Neg  NG 
E3 EAR M NB Neg  COL++ 
E4 EYE M 8 d Neg  HIN+ 
E5 EYE F 74 y + 1085 bp SF 
E6 EYE F 40 y + 1085 bp SF 
E7 EYE F 29 y Neg  NG 
E8 EAR F 1 d Neg  NG 
E9 MOU F 60 y + 1085 bp 
1000 bp 
NF 
E10 EYE M 5 d Neg  NF 
E11 ECA F 58 y Neg  SAU++ 
 
 
E13 EAR F NB Neg  NG 
E15 EAR M NB Neg  NG 
E2 QSW F 24 y Neg  NF 
U1 URI F 61 y Neg  ECO++ 
U2 URI F 46 y + 1085 bp 
1000 bp 
MIXECO++ 
U3 URI F 60 y Neg  ECO++ 
U4 URI M 65 y Neg  NG 
 
Key to Table 3.1. ID = Specimen number, y = years old, d = days old, NB = new born,  M = 
Male, F = Female, EYE = eye swab, EAR = ear swab, MOU = mouth swab, ECA = ethmoid 
cavity swab, QSW = quinsy swab, QAS = quinsy aspirate, AWO = antral washout, URI = urine. 
Culture results from routine microbiology investigations prior to this study: SAU = 
Staphylococcus aureus, SPN = Streptococcus pneumoniae, COL = coliform, MIXCOL = Mixed 
coliform, MRS = Methicilllin resistant Staphylococcus aureus, HAS = Streptococcus pyogenes, 
HIN = Haemophilus influenzae, SMI = Streptococcus millerii, HAS = Streptococcus pyogenes, 
NSA = non-sporing anaerobes, ECO = Escherichia coli, SF = skin flora, NF = Normal flora, NG 
= No growth. 
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Figure 3.12. Age distribution histogram comparing samples with PCR positive 
results for Dolosigranulum pigrum amplicon at 1085 base pairs with total 
number of samples for each age range.  
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Table 3.2 Summary of DNA sequence results 
I.D. Culture 
 
Source Descriptive summary of  DNA sequence results 
A20 MIX 
COL+ 
N/S Match to D. pigrum sequence 
B10 COLI+ 
NF+ 
N/S Match to D. pigrum sequence 
C7 HIN++ 
SPN++ 
MOR++ 
NF++ 
NPA Match to D. pigrum sequence 
C9 NF NPA Match to D. pigrum sequence 
C10 NF NPA Match to D. pigrum sequence 
C13 RSV NPA Match to D. pigrum sequence 
C15 NF NPA Match to D. pigrum sequence 
    
A10 NF T/S Good sequence, but does not match D. pigrum – 100% 
16S rRNA sequence identity with Granulicatella elegans 
and Abiotrophia species 
A12 NF T/S Good sequence, but does not match D. pigrum – 99% 
16S rRNA sequence identity with Granulicatella elegans 
and Abiotrophia species 
B25 NF T/S Good sequence, but does not match D. pigrum – 99% 
16S rRNA sequence identity with Granulicatella elegans 
and Abiotrophia species 
    
A8 HAS 
NF 
T/S Mixed signals, could mean multiple amplicons 
C17 NF NPA Mixed signals, could mean multiple amplicons 
    
 
 
 
Key to Table 3.2: 
NPA = Nasopharyngeal aspirate                      NF =Normal flora 
N/S = Nose swab                                              HIN =H.  influenzae 
T/S = Throat swab                                            SPN = S.  pneumoniae 
 I.D. = Sample number                               MOR = Moraxella species 
                                                                          COLI = Coliform  
                                                             RSV = Respiratory Syncytial virus 
                                                                           HAS = S.  pyogenes 
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Table 3.3 Sequence identification BLAST data produced from sequences A10, 
A12 and B25. 
 
Schedule I.D. and Organism I.D.  Similarity to sequence 
data with 100% coverage 
A10 Throat 
Granulicatella elegans AB252689 
Abiotrophia species AM420130 
  
100% over 340bp 
100% over 340bp 
A12 Throat 
Granulicatella elegans AB252689 
Abiotrophia species AM420130 
Lactobacillus bacterium EU112069 
  
99% over 360bp 
99% over 360bp 
99% over 360bp 
B25 Throat 
Granulicatella elegans AB252689 
Abiotrophia species AM420130 
  
99% over 325bp 
99% over 325bp 
 
 
3.2 Dolosigranulum pigrum antibody enzyme linked immunosorbent assay 
results 
 
The results of the ELISA are shown in Tables 3.4 and 3.5.  A box and whisker 
plot of the results indicated that there could be a difference between the MS and 
the control sera (Figure 3.13).  In order to establish if there was a significant 
difference between the level of anti-D.  pigrum in the MS and control group the 
optical densities (OD) were analysed statistically.  A preliminary test for the 
equality of variances indicated that the variances of the two groups ELISA OD 
were not significantly different F = 1.028, p = 0.455.  Therefore, a two- sample t-
test was performed that does not assume equal variances.  The mean score of 
optical densities of the MS group were (M = 0.911, SD = 0.186, n = 64) 
compared to the control group (M = 0.804, SD = 0.184, n = 65). Using the two-
sample t-test for equal variances, t (9) = 3.306, p < = 0.001 levels of anti-D.  
pigrum in the MS group were significantly different than found in the control 
group. 
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Table 3.4 Anti-Dolosigranulum pigrum optical density enzyme linked 
immunosorbent assay results of multiple sclerosis sera  
 
 
ID OD1 OD2 OD3 Mean 
OD 
 ID OD1 OD2 OD3 Mean 
OD 
36451 0.722 0.639 0.672 0.678  36518 1.176 0.917 1.117 1.070 
36452 0.917 0.717 0.777 0.804  36519 0.893 0.794 0.832 0.840 
36453 0.709 0.552 0.715 0.659  36520 0.847 0.742 0.811 0.800 
36454 1.332 0.971 1.215 1.173  36521 1.043 0.961 1.075 1.026 
36455 1.085 0.868 1.092 1.015  36522 0.862 0.715 0.812 0.797 
36456 1.303 1.177 1.248 1.243  36523 0.469 0.459 0.453 0.460 
36457 0.528 0.432 0.497 0.486  36524 1.190 1.058 1.109 1.119 
36458 0.905 0.708 0.842 0.818  36525 0.820 0.794 0.866 0.827 
36459 0.943 0.922 0.862 0.909  36526 0.914 0.753 0.885 0.850 
36460 1.242 0.997 1.040 1.093  36527 1.006 0.821 0.976 0.934 
36461 0.702 0.675 0.770 0.716  36528 1.174 0.951 1.096 1.074 
36462 1.157 0.822 1.034 1.004  36529 1.151 1.053 1.175 1.126 
36463 1.062 0.856 0.981 0.966  36530 0.910 0.708 0.857 0.825 
36464 1.059 0.998 1.096 1.051  36531 1.062 0.983 1.012 1.019 
36465 0.952 0.832 0.913 0.899  36548 1.239 1.169 1.187 1.198 
36466 0.873 0.805 0.813 0.830  36549 INSF INSF INSF INSF 
36483 0.891 0.528 0.836 0.752  36550 1.086 1.014 1.105 1.068 
36484 1.129 1.021 1.119 1.090  36551 0.692 0.641 0.756 0.696 
36485 1.045 0.935 1.008 0.996  36552 0.742 0.621 0.666 0.676 
36486 1.130 1.032 1.072 1.078  36553 0.759 0.701 0.680 0.713 
36487 1.006 0.871 1.027 0.968  36554 0.931 0.740 0.938 0.870 
36488 0.995 0.922 1.025 0.981  36555 0.982 0.927 1.059 0.989 
36489 0.992 0.862 0.961 0.938  36556 1.077 0.997 1.098 1.057 
36490 1.125 1.096 1.142 1.121  36557 0.741 0.728 0.729 0.733 
36491 0.543 0.465 0.481 0.496  36558 1.178 1.149 1.200 1.176 
36492 0.767 0.660 0.714 0.714  36559 0.806 0.666 INSF 0.736 
36493 0.908 0.756 0.801 0.822  36560 0.777 0.680 INSF 0.729 
36494 1.269 1.176 1.159 1.201  36561 1.067 0.881 0.952 0.967 
36495 0.865 0.788 0.889 0.847  36562 0.793 0.692 0.693 0.726 
36496 1.148 1.146 1.173 1.156  36563 1.104 0.977 1.182 1.221 
36497 0.815 0.658 0.737 0.737  Pos  1.439 1.178 1.381 1.333 
36498 1.000 0.901 0.983 0.961  Neg 0.539 0.481 0.583 0.534 
36515 0.885 0.756 0.791 0.811       
36516 1.034 0.843 0.991 0.956       
36517 1.125 0.948 1.034 1.036       
 
 
Key to Table 3.4 ID = Sample number, OD1 = 1
st
 optical density reading, OD2 = 
2
nd
 optical density reading, OD3 = 3
rd
 optical density reading, Mean OD = mean 
of optical density readings, INSF = insufficient sample for investigation, Pos = 
high reference sample, serum 36490, Neg = low reference sample, serum 36590. 
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Table 3.5 Anti-Dolosigranulum pigrum optical density enzyme linked 
immunoassay results of  control sera (age and sex matched with multiple 
sclerosis sera) 
 
 
 
ID OD1 OD2 OD3 Mean 
OD 
 ID OD1 OD2 OD3 Mean 
OD 
36468 0.760 0.823 1.187 0.923  36573 0.486 0.535 0.847 0.623 
36473 0.690 0.807 1.088 0.862  36574 0.705 0.808 1.078 0.864 
36475 0.360 0.371 0.488 0.406  36575 0.709 0.822 1.184 0.905 
36478 0.693 0.831 1.094 0.873  36576 0.670 0.688 0.997 0.785 
36499 0.926 1.068 1.480 1.158  36577 0.611 0.671 0.969 0.750 
36500 0.459 0.462 0.669 0.530  36578 0.468 0.517 0.753 0.579 
36501 0.562 0.640 0.903 0.702  36579 0.623 0.667 0.965 0.752 
36502 0.692 0.789 1.113 0.865  36580 0.760 0.842 1.220 0.941 
36503 0.672 0.745 0.985 0.801  36581 0.585 0.642 0.888 0.705 
36504 0.439 0.531 0.684 0.551  36582 0.831 0.941 1.310 1.027 
36505 0.510 0.556 0.800 0.622  36583 0.464 0.486 0.718 0.556 
36506 0.683 0.747 1.137 0.856  36584 0.848 0.938 1.313 1.033 
36507 0.350 0.390 0.546 0.429  36585 0.621 0.729 0.994 0.781 
36509 0.911 1.017 1.425 1.118  36586 0.723 0.770 1.158 0.884 
36510 0.740 0.828 1.125 0.898  36587 0.622 0.713 1.015 0.783 
36512 0.703 0.793 1.082 0.859  36588 0.641 0.716 1.032 0.796 
36514 0.538 0.601 0.879 0.673  36590 0.380 0.416 0.630 0.475 
36532 0.774 0.864 1.210 0.949  36591 0.689 0.856 1.203 0.916 
36533 0.661 0.769 1.067 0.832  36592 0.608 0.725 1.036 0.790 
36534 0.793 0.935 1.340 1.023  36593 0.514 0.580 0.809 0.634 
36539 0.558 0.602 0.909 0.690  36594 0.802 0.961 1.369 1.044 
36540 0.534 0.530 0.835 0.633  36595 0.350 0.389 0.483 0.407 
36541 0.563 0.687 0.986 0.745  36596 0.677 0.751 1.111 0.846 
36542 0.829 0.921 1.318 1.023  36597 0.702 0.839 1.205 0.915 
36543 0.703 0.799 1.158 0.887  36599 0.785 0.872 1.220 0.959 
36544 0.884 0.974 1.426 1.095  36600 0.630 0.733 1.015 0.793 
36545 0.563 0.609 0.921 0.698  36601 0.815 0.900 1.358 1.024 
36546 0.413 0.458 0.692 0.521  36602 0.386 0.454 0.703 0.514 
36564 0.752 0.837 1.266 0.952  36603 0.504 0.564 0.841 0.636 
36565 0.621 0.687 1.022 0.777  36604 0.749 0.828 1.209 0.929 
36568 0.734 0.865 1.229 0.943  Pos 0.872 1.056 1.406 1.111 
36569 0.790 0.940 1.363 1.031  Neg 0.416 0.417 0.740 0.524 
36570 0.854 0.933 1.352 1.046       
36571 0.590 0.664 0.933 0.729       
36572 0.748 0.766 1.172 0.895       
 
 
 
Key to Table 3.5 ID = Sample number, OD1 = 1
st
 optical density reading, OD2 = 
2
nd
 optical density reading, OD3 = 3
rd
 optical density reading, Mean OD = mean 
of optical density readings, INSF = insufficient sample for investigation, Pos = 
high reference sample, serum 36490, Neg = low reference sample, serum 36590. 
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density 
 
Figure 3.13. Box and whisker plot of anti-Dolosigranulum pigrum enzyme 
linked immunoassay optical densities results showing median, 1
st
 and 3
rd
 
quartiles and maximum and minimum values. 
1 – Multiple sclerosis sera 
2 - Control sera (age and sex matched with multiple sclerosis sera) 
 
 
 
 
3.3 Western blotting of Dolosigranulum pigrum against multiple 
sclerosis and matched control sera using R6 sera 
 
Examination of the blots (Figure 3.14) showed no common bands with R6 and 
any sera, even the MS sera that had demonstrated elevated levels of anti-D.  
pigrum when tested by ELISA.  This was in contrast to the bands found in a 
previous study using rabbit D.  pigrum antisera R6 (C.W. Gay, 2007). 
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Figure 3.14 . Western blotting of Dolosigranulum pigrum culture supernatant 
against row A multiple sclerosis sera and row B age and sex matched sera using 
the Mini-Protean II (Bio-Rad) and 0.45 µm nitrocellulose membranes.   
The strips were immunoprobed using goat anti-human IgG (Sigma) followed by 
anti-goat IgG horseradish peroxidase (Sigma) and diaminobenzadine (Sigma). 
No common bands were seen with R6 and the patients sera. R6 are Western blots 
from a previous study using the same equipment and Dolosigranulum pigrum 
culture supernatant but  with polyclonal rabbit antisera immunoprobed with goat 
anti-rabbit IgG and then anti-goat IgG horseradish peroxidase with bands 
demonstrating antibody to Dolosigranulum  pigrum arrowed (C.W.Gay, 2007). 
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Chapter 4:                                                
Discussion 
 
4.1 Comparison of culture methods and fluorescein 
isothiocyanate techniques with polymerase chain reaction for the 
study of Dolosigranulum pigrum in multiple sclerosis 
 
FITC labelled antibodies have been successfully employed to detect a variety of 
bacteria (Hoff, 1988, pp. 2949-2952).  The fact that this technique did not prove 
successful in this study, failing to find D.  pigrum in any of the samples, is 
probably due to a lack of sensitivity because of the absence of suitable selective 
media and the polyclonal nature of the rabbit antibody used (C.W. Gay, 2007) 
leading to the inability to differentiate D.  pigrum from the huge number of 
phenotypically similar bacteria found in respiratory samples (Laclaire & 
Facklam, 2000a, pp.2001-2003; Ruoff, 2002, pp. 1129-1133). This difficulty can 
be seen in the fact that the majority of reports of clinical isolates of D.  pigrum 
have come from sites that possess little or no other bacteria and the organism has 
thus been present in pure culture (Tables 1.1 and 1.2).  A search for a selective 
medium for D.  pigrum to aid in the isolation of the organism is unlikely to be 
successful as the bacteria are sensitive to penicillin and vancomycin (Cho et al., 
2011, pp. 18-22; Hall et al., 2001, pp. 1202-1203; Hoedemaekers et al., 2006, pp. 
3461-3462; Lécuyer et al., 2007, pp. 3474-3475) as are many of the other 
catalase negative, Gram positive cocci found in the nasopharynx (Laclaire & 
Facklam, 2000a, pp.2001-2003; Ruoff, 2002, pp. 1129-1133).  Yet the intuitive 
problems inherent in isolating D.  pigrum from mixed cultures are not the only 
difficulty encountered when trying to culture these slow growing bacteria.  Two 
cultures of the naso-pharyngeal samples, C11 and C18, in this study yielded no 
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growth even after prolonged incubation, despite the PCR detecting D.  pigrum.  
This suggests that either the bacteria were non-viable or so fastidious in their 
requirements that they were unable to grow on the bacteriological plates used.  
The difficulties of culturing this bacterium have also been encountered by 
Lucuyer (Lécuyer et al., 2007, pp. 3474-3475) in a patient with pneumonia and 
septicaemia.  D.  pigrum was cultured in abundance from bronchial aspirates but 
failed to grow from the blood.  D.  pigrum was identified from both sites using 
16S rRNA gene sequencing. It would seem that the culture of D.  pigrum using 
conventional bacteriological techniques is still fraught with difficulties.  There 
are also problems with the phenotypic identification of this slowly growing 
bacterium.  Phenotypically D.  pigrum closely resembles bacteria such as 
Ignavigranum species, Alloiococcus species and Facklamia languida (Ruoff, 
2002, pp. 1129-1133).  It is described as being Gram positive and appearing in 
pairs and tetrads, being catalase and oxidase negative with disc tests for 
pyrrolidonyl arylamidase (PYR) and leucine aminopeptidase (LAP) showing a 
positive reaction (Laclaire & Facklam, 2000a, pp.2001-2001; Ruoff, 2002, pp. 
1129-1133) but this is not enough to differentiate it from a number of 
phenotypically similar organisms (Table 4.1).  Looking at Table 4.1 it would 
seem that the use of production of PYR and LAP for identification is a relatively 
simple means of identification but this is complicated by strain variability to 
these reactions, with Lactococcus strains in particular showing variable reactions 
in the PYR test (Ruoff, 2002, pp. 1129-1133).  Similarly the use of microscopic 
morphology to differentiate Dolosigranulum pigrum, Facklamia languida, 
Rothia mucilaginosa, Gemella haemolysans from Vagococcus, Lactococcus, 
Ignavigranum, Abiotrophia, Granulicatella, Gemella spp. other than G.  
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haemolysins  or Facklamia other than Facklamia languida is in practice a highly 
subjective process,  with bacteria in pairs appearing to be in either chains or 
clusters.   
 
Table 4.1 Reactions of miscellaneous catalase-negative Gram positive cocci in 
basic phenotypic tests 
 
Result of 
phenotypic 
test 
Morphology Possible identity 
PYR LAP 
+ + Clusters Dolosigranulum pigrum, Facklamia languida, 
Rothia mucilaginosa, Gemella haemolysans 
+ + Chains Vagococcus, Lactococcus, Ignavigranum, 
Abiotrophia, Granulicatella, Gemella spp. 
other than G.  haemolysins  or Facklamia other 
than Facklamia languida 
+ - Chains Globicatella, Dolosicoccus 
+ - Clusters Aerococcus viridans, Helcococcus 
- + Clusters Aerococcus urinae, Pediococcus 
- + Chains Viridans streptococci 
- - Chains Leuconostoc 
 
Key to Table 4.1. PYR = production of pyrrolidonyl arylamidase, LAP = 
production of leucine aminopeptidase. Results shown are typical of the majority 
of strains, reactions of individual strains may vary. 
Chains refers to cocci in pairs and chains, clusters refers to cocci that form pairs, 
tetrads and irregular groups. 
Lactococcus strains may show variable reactions in the PYR test. 
 
 
D.  pigrum grows in 6.5% sodium chloride broth but not on bile aesculin, and 
gives negative results for production of urease, and motility (Laclaire & 
Facklam, 2000, pp. 2001-2001) but none of these reactions or properties are 
suitable for consistently identifying cultures of  D.  pigrum.  Esculin hydrolysis 
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can be used to distinguish D.  pigrum from other catalase negative, PYR and 
LAP positive organisms, but esculin hydrolysis can be difficult to interpret and it 
can take up to 14 days to become positive (Hall et al., 2001, pp. 1202-1203).    
Identification by commercial identification kits is also unsatisfactory.  LaClaire 
and Facklam, (2000b, pp. 2037-2042) evaluated the performance of three 
commercially produced rapid identification systems for the identification of D.  
pigrum, Ignavigranum ruoffiae and Facklamia species.  All three systems, the 
bioMerieux rapid ID32 Strep, the BBL Crystal rapid Gram positive identification 
and the Remel IDS RapID STR (IDS) systems, misidentified the organisms. The 
bioMerieux API 20 Strep identified  D.  pigrum  as G.   haemolysans 
(Hoedemaekers et al., 2006, pp. 3461-3462; Lécuyer et al., 2007, pp. 3474-3475) 
and the API rapidID32 Strep was again found to be unable to identify D.  pigrum 
(Lécuyer et al., 2007, pp. 3474-3475).  The correct identification can, for the 
present, only be gained by using a 16S rRNA PCR (Cho et al., 2011, pp. 18-22; 
Hall et al., 2001, pp. 1202-1203; Hoedemaekers et al., 2006, pp. 3461-3462; 
Lécuyer et al., 2007, pp. 3474-3475).  Because of the difficulty with culture 
techniques and subsequent identification, investigators have concluded that 
molecular methods of detection, such as employed in this study, are the future for 
the study of the numerous catalase negative Gram positive cocci emerging as 
opportunistic pathogens (Bosshard, Abels, Altwegy, Bottger & Zbinden, 2004, 
2065-2073) which includes D.  pigrum (Cho et al., 2011, pp. 18-22; Lécuyer et 
al., 2007, pp. 3474-3475).  The importance of these bacteria extends to the 
bacterial toxins hypothesis of MS which posits that a cocktail of transportable 
antigens from a number of bacteria located in the nasopharynx are responsible 
for MS (Gay, 2013, pp. 213-232).  The catalase-negative, Gram positive cocci 
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group found in the upper respiratory tract have been reviewed by Ruoff (2002, 
pp. 1129-1133) and contains a number of viridans streptococci, historically the 
best recognised members of this large and diverse group of bacteria.  All of the 
viridans streptococci are pyrrolidonyl arylamidase negative and leucine 
aminopeptidase positive, unlike D.  pigrum which is pyrrolidonyl arylamidase 
positive and leucine aminopeptidase positive (Ruoff, 2002, pp. 1129-1133).  
Most of these streptococci are α-haemolytic on blood agar, leading to their name 
of viridans, but β-haemolytic and non-haemolytic strains have been described.  
The salivarius group, Streptococcus salivarius and Streptococcus vestibularis, 
are non-haemolytic or α-haemolytic and produce extracellular polysaccharides 
and are known to cause septicaemia in neutropaenic patients (Ruoff, Miller, 
Garner, Ferraro & Calderwood, 1989, pp. 305-308).  The bovis group are non-
enterocococcal Lancefield group D streptococci that can be divided into many 
biotypes and, like the salivarius group, produce extracellular polysaccharide-
forming bio-types.  They can cause septicaemia, endocarditis and also have an 
association with colonic cancer (Ruoff et al., 1989, pp. 305-308).  The mutans 
group containing Streptococcus mutans and Streptocococcus sobrinus are found 
in the oral cavity and are associated with dental caries and endocarditis, and 
produce extracellular polysaccharides (Coykendall, 1974, pp. 327-338). The 
mitis group contains S.  pnemoniae, Streptococcus mitis and Streptococcus oralis 
with the former being a recognized pathogen of the lower respiratory tract, but is 
also responsible for other infections ranging from meningitis to conjunctivitis in 
susceptible individuals, whilst the latter two are found in infections in 
neutropaenic patients where S. mitis can display penicillin resistance (Doern, 
Ferraro, Bruggemann & Ruoff, 1996, pp. 891-894).  The milleri group of 
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Streptococcus anginosus, Streptococcus intermedius and Streptococcus 
constellatus may be α-, β- or non-haemolytic and do not produce extracellular 
polysaccharide but are associated with serious purulent infections throughout the 
body (Bert, Bariou-Lancelin, & Lambert-Zechovsky, 1998, pp. 385-387). As 
well as the streptococci there are a number of other catalase-negative Gram 
positive cocci.  Leuconostoc and Pediocococcus display intrinsic high level 
vancomycin resistance and are α- or β- haemolytic (Ruoff, 2002, pp. 1129-1133).  
Members of both genera are PYR negative and LAP positive (Ruoff, 1999, pp. 
306-315). Leuconostoc form cocci in pairs and short chains (Handwerger, 
Horowitz, Coburn, Kolokathis & Wormser, 1990, pp. 602-610), whilst 
Pediococcus form cocci in clusters (Barros, Carvalho, Peralta, Facklam & 
Teixera, 2001, pp. 1241-1246). Both bacteria have been implicated in 
septicaemia and other infections in compromised hosts (Ruoff, 1999, pp. 306-
315).  Gemella are α-haemolytic and are associated with endocarditis, meningitis 
and other infections.  There are four species: Gemella haemolysans, Gemella 
morbillorium Gemella bergeriae and Gemella sanguinis and have been isolated 
from a range of infections including endocarditis and meningitis (Facklam & 
Elliot, 1995, pp. 479-495). D.  pigrum was originally misidentified as a Gemella 
(Laclaire & Facklam, 2000a, pp. 2001-2003).  Rothia mucilaginosa can range 
from catalase positive to negative and is usually non-haemolytic.  It is an 
opportunistic pathogen found in cases of endocarditis and meningitis.  
Aerococcus viridans as the name implies is α-haemolytic and is an infrequent 
cause of infection in compromised hosts and is PYR positive and LAP negative 
(Christiansen, Vibits, Ursing & Korner, 1991, pp. 1049-1053). Aerococcus 
urinae can cause urinary tract infections and endocarditis and is PYR negative 
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and LAP positive (Kawamura et al., 1995, pp. 793-803).  Lactococcus and 
Vagococcus resemble streptococci, with Lactococcus having been isolated from 
cases of endocarditis.  Globicatella, Facklamia, Ignavigranum and Dolosicoccus  
have been found in blood cultures (Collins et al., 1999a, pp. 97-101; Collins et 
al., 1999b, pp, 1439-1442), and Facklamia hominis has recently been found in a 
case of infectious endocarditis (Ananthakrishna et al., 2012, pp. 1-3).  The non-
haemolytic slowly growing Helcococcus kunzii has been described as an agent of 
wound infections (Woo et al., 2005, pp. 6205-6208) and a new species 
Helcococcus sueciensis has also been found in human wounds (Collins, Falsen, 
Brownlee & Lawson, 2004, pp. 1557-1560).  Abiotrophia and Granulicatella are 
Gram-positive cocci in pairs and chains, which are PYR and LAP positive, and 
are discussed in greater detail in section 4.2.  With such a large number of 
phenotypically similar organisms to D.  pigrum, and no selective media or 
reliable biochemical identification systems currently available, the best method 
to look for D.  pigrum using bacteriological culture is a rabbit antibody to D.  
pigrum developed by C.W. Gay (2007).  This is a polyclonal antibody, and on 
the evidence of this study the FITC-labelled antibody technique was 
insufficiently sensitive to detect the presence of D.  pigrum from clinical 
specimens, and PCR appears to be the best method for detection and 
identification of the organism. 
Widespread use of PCR has led to revolutionary changes in the phylogeny and 
taxonomy of bacteria. The use of 16S rRNA sequences for the identification of 
bacteria has developed dramatically in the last decade and has been particularly 
useful for the identification of slowly growing fastidious organisms, such as 
members of the catalase-negative Gram positive cocci group like D.  pigrum, that 
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are difficult to grow by conventional bacterial culture methods.  Short sequences 
of 450-650 base pairs are usually sufficient for most identifications, and a large 
number of bacteria have had their 16S rRNA wholly, or like D.  pigrum, partially 
sequenced.   
An area of concern with using PCR for this project was the number of samples 
received in Amies charcoal transport medium.  This medium was developed to 
stop dessication, provide an Eh gradient for anaerobic bacteria, and adsorb out 
toxins to allow the growth of bacteria during transportation, and there was 
concern that it might inhibit DNA extraction.  However, several publications 
have concluded that no inhibition occurs using Amies medium for PCR work 
(Aliyu et al., 2004, pp. 1029-1035; Cloud, Hymas & Carroll, 2002, pp. 3833-
3840), and a similar DNA extraction system (Roche MagNA pure) to that 
employed in this study was successfully used for DNA extraction of 
Fusobacterium necrophorum from Amies swabs by Aliyu and co-workers (2004, 
pp. 1029-1035). 
 
4.2 Sequence analysis of polymerase chain reaction products  
Although the data collected from the sequencing results is too small to draw any 
definitive conclusions, it is clear that under the running conditions employed the 
PCR is not entirely specific for D.  pigrum, as both mixed and non-specific 
amplification occurs.  
Analysis of the 12 sequenced results (Table 3.2) revealed three patterns:-  
1) Successful unambiguous amplification of the D.  pigrum 16S rRNA gene 
(7/12). 
2) Mixed, difficult to distinguish signals (2/12). 
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3) A clear unambiguous sequence that does not correspond to the D.  pigrum 16S 
rRNA gene (3/12). 
In the case of the latter, a single amplicon that did not match the D.  pigrum  
16S rRNA was found in B25, A10 and A12.  Analysis using the Basic Local 
Alignment Search Tool (BLAST) of the amplicons showed a remarkable 
similarity, demonstrating between 100% and 97%  16S rRNA sequence identity 
with a number of  identified (cultured and named) and unidentified sequences 
(Table 3.3). 
Table 3.3 shows that in the three instances of non-D.  pigrum detection the 
amplicon produced was consistent.  The same sequences with the same accession 
numbers were identified from the three sequences from three different throat 
swabs.  Amongst the sequences from known sources that with the highest 
sequence identity was the 16S rRNA gene sequence of Granulicatella elegans 
and the 16S rRNA sequence of Abiotrophia species (see Figure 4.1).  
Abiotrophia species were previously known as nutritionally variant streptococci 
(Frenkel & Hirsch, 1961, pp. 728-730) that exhibited satellitism around colonies 
of other bacteria.  The bacteria are part of the normal flora of the human pharynx, 
urogenital and intestinal tract but have been implicated in cases of infective 
endocarditis (Bouvet, 1995, pp. 24-27; Ruoff, 1991, pp. 184-190) and 
septicaemia and bacteraemia (Christensen & Facklam, 2001, pp. 3520-3523). 
G.  elegans is a fastidious bacterium that used to belong to the genus Abiotrophia 
(Collins & Lawson, 2000, pp. 365-369) and both it and Abiotrophia are 
taxonomically related to D.  pigrum (Figure 4.1).  It is found in the oral cavity 
(Ohara-Nemoto et al, 2005, pp. 1405-1407) and has been associated with 
infective endocarditis (Ohara-Nemoto et al., 2005, pp. 1405-1407; Casalta et al., 
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2002, pp. 1845-1847).  There are now three other species in the genus 
Granulicatella, Granulicatella adiacens, Granulicatella para-adiacens and 
Granulicatella balaenopterae (Christensen & Facklam, 2001, pp. 3520-3523; 
Collins & Lawson, 2000, pp. 365-369) and all of them have been reported as 
causing infective endocarditis. Christian and Facklam (2001, pp. 3520-3523) 
identified 25 cases of infective endocarditis (IE) caused by G.   adiacens and one 
case by G.  elegans.  Roggenkamp and co-workers (Roggenkamp et al., 1998, pp. 
100-104) also reported a case of IE caused by G.  elegans, and Kanamoto, Sato 
and Inoue (2000, pp.492-498) reported 45 cases of IE including 15 of G.  
adiacens, 13 of G.  para-adiacens and eight of G.  elegans.  The genus 
Abiotrophia should now be restricted to Abiotrophia defective (Collins & 
Lawson, 2000, pp. 365-369) and it has been found in nine cases of IE (Kanamoto 
et al., 2000, pp. 492-498).   
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Figure 4.1: Dendrogram representing the phylogenetic relationship between 
Granulicatella elegans and Dolosigranulum pigrum (arrowed) among members 
of the Streptococcaceae. 
The tree was derived from a 1,304-bp fragment of the 16S rRNA gene and was 
constructed by using the neighbor-joining method. Bootstrap values, expressed 
as a percentage of 1,000 replications, are given at the branching point 
(Casalta et al., 2002, p. 1846). 
 
In order to establish the reasons for the undesired amplification of non-D.  
pigrum sequences, and to postulate whether their amplification was due to 
unstable PCR running conditions or non-specific primers, a G. elegans rRNA 
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gene sequence demonstrating 99% homology to rRNA gene sequence B25 was 
collected and aligned with the known D.  pigrum 16S rRNA gene sequence.  This 
alignment was then used to compare the D.  pigrum primer regions to the G. 
elegans rRNA gene sequence: 
 
FORWARD 
 5’ TAGGTGGATTGGTCGCATGA 3’  D. pigrum  
 5’ TAGGTTCTTGAGTCGCATGA 3’  G. elegans 
 5’ TAGGTTCTTGAGCTGCATGG 3’  Abiotrophia sp.    
  
REVERSE (REVERSED AND COMPLEMENTARY)  
 5’ GGGATCGCTGCTCGTTGTAC 3’  D. pigrum 
 5’ GAGTTCGCTGCTCGTTGTAC 3’  G. elegans 
 5’ GAGTTCGCTGCTCGTTGTAC 3’  Abiotrophia sp. 
*Shading corresponds to mismatches to the primers designed to amplify D. pigrum  
 
Figure 4.2: The D.  pigrum primer regions.  
This is based on the D.  pigrum 16S gene (X70907) aligned the G. elegans and 
Abiotrophia sp. sequences corresponding to A10, A12 and B25 showing some 
unique D.  pigrum bases, but with a high degree of 3‟ similarity. 
 
As can be seen from Figure 4.2 many of the bases in the 3' region of   
G.  elegans are identical to D.  pigrum and could therefore be causing the 
interference and false positive results.  This is a flaw in the primer design as one 
of the factors in primer specificity is the occurrence of unique bases at the 3' end, 
because the taq polymerase works from 3' to 5', thus preventing attachment and 
polymerisation of undesired DNA.  Developmental work on the primer by 
Charles Gay as part of an unpublished post-graduate thesis (2009) had 
demonstrated that the adenine at the 3' end of the forward primer although 
variable is not unique to D.  pigrum.  It is possible, therefore, that the PCR might 
not be specific in the few instances in which adenine does exist in this position in 
other species. 
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Analysis of the sample types demonstrated some trends 
Naso-pharyngeal aspirates 
 Five of the NPA amplicons corresponded to D.  pigrum, demonstrating a single 
well matched amplicon.  C17 gave mixed signals, suggesting that more than one 
gene was amplified, or that mistakes were made during the polymerase reaction 
(poor PCR fidelity). 
Nose swabs  
 The two amplicons that were sequenced from this source demonstrated an 
amplicon that matched the D.  pigrum gene.  One sequence, A20 was not very 
high above the background, suggesting that there could have been some low 
level amplification of other gene sequences, or mistakes during the polymerase 
reaction (poor PCR fidelity). 
Throat  
 None of the four throat amplicons revealed a D.  pigrum sequence.  Three of 
them had a clear signal, but this did not correspond to D.  pigrum.  The other 
sequence, A8, demonstrated mixed signals, again suggesting that more than one 
gene was amplified, or that mistakes were made during the polymerase reaction 
(poor PCR fidelity).   
Each type of sample comes from sites with very different environments 
containing different bacterial flora and therefore different DNA.  For the 
molecular detection of D.  pigrum the oropharyngeal region appeared to be the 
most problematic with no D.  pigrum detected but Abiotrophia species, and 
particularly G.  elegans, posing a problem for the primers used.  These bacteria 
are not normally found in the nasal or nasopharyngeal regions (Ruoff, 1991, pp. 
184-190; Bouvet, 1995, pp. 24-27), and so although the primers were not ideal, 
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the fact that they contained D.  pigrum specific bases that may be sufficient for 
specific amplification, means that they may be utilized to screen for D.  pigrum 
in nasal and nasopharyngeal specimens.  Carriage of D.  pigrum is of particular 
interest from these sites because of the link found by Gay and co-workers 
between MS and sinusitis (Gay et al.,1986, pp. 815-819; Dick and Gay, 1988, pp. 
25-35) leading to the bacterial toxins hypothesis of the cause of MS (Gay, 2007, 
pp. 105-112). 
A further study is necessary to fully evaluate the PCR.  During the development 
of the PCR as part of an unpublished post-graduate thesis (Gay, 2009) it was 
uncertain if 30 cycles should be used instead of 35 cycles, as using a relatively 
high number of cycles (35) can lead to polymerase activity saturation, which is 
known to  be a cause of a high level of mistakes during the elongation step.  This 
can lead to the erroneous results and non-specific amplification seen in this 
study.  However, 30 cycles could lead to a crucial loss of sensitivity and the 
failure to detect small numbers of D.  pigrum and so it was decided to use 35 
cycles.  A solution to this problem could be to use a two step (nested) technique 
which would maximize the sensitivity whilst maintaining the specificity of the 
PCR.  This has been used in detecting Histoplasma capsulatum in human tissue 
(Bialek et al., 2002, pp. 1644-1647). Raising the annealing temperature by a 
degree or two should also be attempted as this may help to increase the 
specificity, which could be crucial in the early stages of the PCR, helping to 
eliminate non-specific amplicons.  Therefore, an adjustment to the crucial ratios 
of primer to template and polymerase to template may result in an improved 
specificity, and a further study comparing the PCR with both running conditions 
is indicated to ensure that the sensitivity is not compromised.  If this does not 
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yield acceptible results, then the primers will have to be redesigned so that a PCR 
possessing high sensitivity and specificity is produced which can be used to 
screen for D.  pigrum in clinical specimens.  The problem is that to date the 16S 
rRNA is the only part of the D.  pigrum genome that has been sequenced. This 
makes designing a species specific PCR difficult as many other species will have 
closely homologous sequences, so the task of incorporating D.  pigrum specific 
bases into highly specific primers is made much more difficult.  The future thus 
relies upon the sequencing of the whole genome of D.  pigrum so that there is a 
better chance of designing a highly specific primer. 
 
4.3 Detection of Dolosigranulum  pigrum  
From the sequencing results it would appear that any PCR product with a single 
band at 1085 bp is amplifying D.   pigrum, but any product producing a double 
band is producing mixed amplicons or detecting Abiotrophia species or  
G.  elegans.  If an assumption is made that this is also true of the other PCR 
results that were not sent for sequence analysis then in total there were nineteen 
positive specimens out of eighty eight (21%).  There were twelve males to seven 
females, ranging in age from seventy three years to 8 days in age, with the 
majority being under a year old (11, 58%) indicating that acquisition of D.  
pigrum  occurs at a very early age.  The majority of samples matching with the 
D.  pigrum gene were naso-pharyngeal aspirates (10, 55%), with seven from 
throat swabs and two from nose swabs.  This is consistant with LaClaire and 
Facklam‟s findings in 2000 (pp. 2001-2003) (Table 1.1) which detected the 
bacterium in respiratory samples including naso-pharyngeal specimens. The 
results of the microbiological testing of the samples before they were used in this 
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study were accessed.  This gave some idea of the microbial flora present, 
although it was an incomplete picture as non-pathogenic organisms were 
reported as “normal flora” or “skin flora”, or not fully identified and reported as 
“coliforms”. There appeared to be no particular association with recognized 
pathogens, with six samples matching with the D.  pigrum gene containing 
pathogens and thirteen no pathogens.  It would be interesting to perform another 
study using the D.  pigrum probes from this study and fully identifying and 
characterizing any bacteria found, especially from nasal and naso-pharyngeal 
samples, which would lead to a greater understanding of the microbial 
communities found in the upper respiratory tract.  The current study indicates 
that D.  pigrum is present from an early age (Table 3.1), though whether it is 
causing disease or is present as a permanent or transitory part of the normal flora 
can not be said.  Recent evidence supports these findings with Laufer and co-
workers finding D.  pigrum  in nasal swabs of children aged 6 to 78 months in a 
study on the bacterial flora of the nasal cavity (Laufer et al., 2011).  The study 
concluded that D.  pigrum was a member of the normal flora and imparted a 
protective effect against colonization leading to otitis media from S.  pneumoniae  
in children.   
 
4.4 Enzyme linked immunosorbent assay and Western blotting 
 
The development of ELISA tests to look for antibody has been used successfully 
to look for equine influenza virus (Denyer, Crowther, Wardley & Burrows, 1984, 
pp. 609-620), and the use of ELISA followed by Western blotting for antibody 
investigations are a proven method of investigating diseases, and have been used 
as an algorithm for HIV testing  (“HIV Assays…”, 2004, pp. 9-15), and for 
published studies (Figueroa et al., 2000, pp. 57-62).  
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In this study there was a statistically significant difference  in antibody levels to 
D.  pigrum in the MS group compared with age and sex matched controls.  
Western blotting of 15 of these sera failed to detect bands common to D. pigrum.  
Raised intrathecal and blood antibodies to a number of organisms have been 
reported in MS (Salmi, Reunanen, Ilonen & Panelius, 1983, pp. 241-249; Salmi, 
Viljanen & Reunanen, 1981, pp. 333-341; Vartdal, Vandvik & Norrby, 1980, pp. 
248-255) but these findings were not uniformly accepted as other studies failed 
to find a significant difference between MS and controls (Norrby, 1978, pp. 1-39; 
Vandvik & Norrby, 1989, pp. 769-771).  It is possible that the failure to find 
bands common to D.  pigrum on Western blotting may be due to a lack of 
sensitivity caused by using the culture supernatant of whole cell D.  pigrum.  
Equally the findings of raised antibody levels in this study may indicate that 
antibodies to  D.  pigrum are a biological marker suggestive of leakage of 
bacterial products from the upper respiratory tract into the central nervous system 
which may initiate MS.  Indeed, using isoelectric focusing with antigen 
imprinting to investigate oligoclonal immunoglobulin bands (OCBs) in MS 
patients, Jorge (1995), found evidence of reaction between OCBs and the 
supernatant of cultures of staphylococci.  The origin of OCBs found in MS has 
never been explained although they are not directed to any viruses that have been 
studied in conjunction with MS or to CNS antigens (Mehta, Patrick, Mehta & 
Wiseniewski, 1987, pp. 746-751).  This has led to them being dismissed as 
„nonsense antibody‟ without any antigenic specificity (Patersson & Whitacre, 
1981, pp. 111-117).  The finding in this study that systemic levels of antibody are 
elevated in MS raises the question could the OCBs in MS be formed in response 
to bacterial toxins leaking into the CNS.   
  98 
Transportable products, such as toxins, made by Gram positive bacteria 
demonstrate cross reactivity across species (Dinges, Orwin & Schlievert, 2000, pp. 
16-34) and such cross reactivity has been found with staphylococcal enterotoxin B 
(sphingomyelinase) and a 28 kDa  D.  pigrum protein ( C.W. Gay, 2007) (Figure 
4.3).   
 
 
Figure 4.3. A cross reactive 28 kDa band between Staphylococcus aureus and 
Dolosigranulum pigrum. Demonstrated using anti-Staphylococcus aureus 
enterotoxin B antibody against Dolosigranulum pigrum peptides (lane 1, 2), and 
anti- Dolosigranulum pigrum antibody (rabbit R3 and R4) against 
Staphylococcus aureus enterotoxin B (lanes 5, 6). (C.W. Gay, 2007). 
 
This D.  pigrum protein may be a sphingomyelinase, as this toxin is associated with 
hot/cold haemolysis, something which D.  pigrum demonstrates (Figures 1.6 and 
1.7), 
As mentioned it seems likely that any such involvement of bacterial toxins in MS 
will be polymicrobial, and in the light of the well documented carriage of S.  aureus 
in the nasal tract (Kluytmans, van Belkum & Verbrugh, 1997, pp. 505-520) and 
Gay‟s (2013, pp. 213-232) finding  using immunocytology of an IgG from one of 
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the rabbits(R3) detecting antigen ('R3.89') in association with early primary MS 
lesions. Evidence from mass spectroscopy suggested that the antigen was 
staphylococcal neutral sphingomyelinase (Gay, 2013, pp. 213-232).  Antibody  to 
R3.89 was also detected in the other rabbits (R4, R5 and R6) at lower titres (D. 
Gay, personal communication, February  04, 2009).  Many Gram positive bacteria, 
produce these toxins which have been associated with neurological diseases 
(Uyeda, Gerstl, Smith & Carr, 1966, pp. 143-146).  Sphingomyelinase hydolyses 
the phosphodiester bond of sphingomyelin in target cells and the susceptibility of 
these cells appears to be directly related to the sphingomyelin content of their cell 
membrane.  Sphingomyelinase from external sources, such as from bacteria, results 
in the release of ceramide as a result of extensive endocytosis of plasma membranes 
(Zha et al., 1998, pp. 39-47).  This release of ceramide triggers the export of internal 
cellular sphingomyelinases to the outer surface of the cellular plasma membrane 
leading to more sphingomyelin being hydrolysed in a chain reaction which results 
in the initiation of cell apoptosis (Rebillard et al., 2007, pp. 7865-7874).  
Oligodendrocyte apoptosis has been induced in cell culture using staphylococcal 
neutral sphingomyelinase (Jana & Pahan, 2007, pp. 184-193) mediated by ceremide 
(Lee et al., 2004, pp. 123-131), and Barnett and Prineas (2004, pp. 458-468) have 
proposed that oligodendrocyte cell death is a primary event in early MS and occurs 
in pre-demyelinating lesions. Whilst this may be true, and oligodendrocytes 
certainly demonstrate a high susceptibility to neutral sphingomyelinases, it is 
unlikely that they are the sole mediators for the development of MS.  It is more 
likely that they are one of a number of transportables produced by a variety of 
species within the flora of the nasopharynx which act together to manipulate the 
host immune response.  Evidence for this happening has been seen with the 
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staphylococcal toxic shock syndrome toxin (TSST-1), where the superantigenic 
mitogenic signal of the toxin has been augmented by the presence of 
sphingomyelinase (Huesby et al., 2007, pp. 8719-8726).  It is this pathogenic 
heterogeneity which makes it difficult to establish which are the key toxins 
responsible for the development of MS. 
 
4.5 Future work to validate the bacterial toxins hypothesis 
Although the primers for the PCR used for this thesis need refining, this study 
found D.  pigrum in the nasal tract and nasopharynx.  From this location the 
bacteria may be able to gain entry to the sinuses, and from there export toxins into 
the CNS.  Further work is indicated to establish the composition of the bacterial 
flora of the nasopharynx in MS, as the toxins which intiate the disease may be 
polymicrobial.  Such studies should be performed using a matched control group to 
see if there are any differences in the bacterial flora in MS, and should include MS 
patients at different stages of their disease to see if there is any difference in the 
composition of the flora in early stages of the disease.  Molecular studies, using a 
panel of primers from the 16S rRNA of bacteria, should be included as there are a 
number of fastidious bacteria, including the catalase negative Gram positive cocci 
found in the nasopharynx, which are difficult to culture on bacteriological media 
(Casalta et al., 2002, pp. 1845-1847).  A recent study on the bacterial flora of 
normal adult nasal cavities highlighted the benefits of using molecular methods 
(Cho et al., pp. 18-22).  The researchers used bacteriological culture methods and 
polymerase chain reaction-denaturating gradient gel electrophoresis (PCR-DGGE) 
of 16S rRNA gene fragments on 19 nasal swabs.  On culture only nine species 
were detected, with Staphylococcus epidermidis being the most frequently detected 
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followed by Staphylococcus aureus.  The detection rate of the other bacteria was 
very low.  In contrast using PCR-DGGE  23 different kinds of bacteria were 
detected of 9 genera: Staphylococcus, Dolosigranulum, Bacillus, Corynebacterium, 
Enterobacter, Actinobacterium, Hafnia, Moraxella and Clostridium.  
Staphylococcus species and Enterobacter aerogenes were isolated most frequently.  
Staphylococci have recently been implicated in MS (Gay, 2013, pp. 213-232).  It is 
known that 30-40% of S.  aureus isolates from human infections are β-toxin 
positive, with nasal carriage in the general population of 11% (Hedström & 
Malmqvist, 1982, pp. 217-220).  Furthermore some strains produce an incredible 
500 μg toxin per ml in culture (Huesby et al., 2007, pp. 8719-8726) and this raises 
the possibility that particular toxigenic strains of  S.  aureus may be specifically 
associated with MS.  Mulvey and co-workers (2011, pp. 397-403) have used 
genetic techniques to identify enterotoxigenic strains of S.  aureus in MS patients 
and the nasal flora of MS patients should now be examined for high secreting 
toxigenic strains.  Such work may lead to the exciting development of a specific 
laboratory test for MS.  Elevated serum antibody levels were found in this study in 
MS patients, but they were not found to be specific for D.  pigrum.  This may be a 
sensitivity issue as the Western blotting used supernatant from whole cell culture of 
D.  pigrum.  Further research of  D.  pigrum would enable specific purified specific  
toxins to be used to establish if there is an elevation of anti-D.  pigrum in MS.  The 
creation of an ELISA test for screening MS CSF for anti-D.  pigrum is also 
indicated.  Further genetic sequencing of  D.  pigrum should proceed to enable  
specific primers to be made both for further identification and toxin studies, which 
would help to prove if D.  pigrum were involved in MS.  Such genetic information 
could also be used in studies to see if the sequences for the toxins are analogous 
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with the the exotoxins of other bacteria.  This is pertinent as, already discussed, D.  
pigrum may produce a sphingomyelinase which cross-reacts with staphylococcal 
sphingomyelinase, a bacterial toxin that has recently been proposed as a possible 
instigator of MS (Gay, 2013, pp. 213-232).  A further study employing an ELISA to 
look for anti-sphingomyelinase in MS in serum and CSF is therefore indicated.   
Sphingomyelinase could be looked for using PCR in „nose blows‟ or nose swabs.  
This technique could also be used to screen MS CSF for the presence of bacterial 
products.  The intranasal inoculation of transportable toxins such as staphylococcal 
sphingomyelinase and enterotoxins thought to be involved in the immune 
dysregulation of MS using animal models such as rats should also take place.  Such 
studies on bacterial products or toxins might go some way to seeing if the bacterial 
hypothesis of MS is valid or not.                         
Finally the use of a radiographic marker into the nose, and subsequent tracking of 
its progress using magnetic resonance imaging could establish a potential route of 
access of bacterial products behind the blood-brain barrier, and directly to the CNS 
which would help to validate the bacterial toxins hypothesis.  If such a route is 
proven then it would also allow the entry of therapeutic drugs for a number of 
neurological diseases, including MS, directly into the CNS (Wen et al., 2011, pp. 
131-138; Gay, 2012, pp. 154-155).  This may have implications in MS as it has 
been argued that early treatment of respiratory bacterial infections in the disease 
may have a beneficial effect (Herrmann et al., 2006, pp. 4841-4848), although the 
use of penicillin was found not to be associated with a decreased risk of MS 
(Alonso, Jick, Jick & Hernan, 2006, pp. 997-1002). 
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4.6 Conclusions 
The main conclusions from the study were: 
 
 An ELISA to screen for antibodies to D.  pigrum in the serum of 65 MS 
and matched controls was successfully designed and run.  Levels of 
detectable IgG associated with D.  pigrum in the MS group were found to 
be significantly different than the control group, p < = 0.001. 
 Using Western blotting 15 of the sera demonstrating detectable antibody 
levels in their sera in the ELISA, along with their matched controls were 
run against D.  pigrum NCIMB 702975 culture supernatant.  There was a 
lack of common bands between the MS sera and with R6 rabbit anti-D.  
pigrum sera from a previous study (C.W. Gay, 2007), but this may be due 
to the fact that supernatant of whole cell D.  pigrum was used in the 
current study.  Research into D. pigrum toxins and sequencing of the 
bacterium in its entirety would provide opportunities to further test an 
association between D. pigrum and MS. 
 Eighty eight respiratory, eye and ear swabs and various body fluids were 
screened for D.  pigrum by culture and anti-D . pigrum (R3) / fluorescein 
isothiocyanate microscopy.  All were negative. These findings concur 
with other studies that conclude that the detection of the bacterium should 
be performed by molecular means using PCR. 
 The PCR used in this project successfully detected D.  pigrum in nasal 
and naso-pharyngeal specimens, proving that the bacteria were in the 
right location to be able to leak toxins into the CNS in MS.  The PCR was 
less successful in other sites, especially in the oropharynx where the 
closely related G.  elegans and Abiotrophia gave false positive reactions.    
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 The bacterial toxin hypothesis was not disproved, D.  pigrum being found 
in the nasopharynx where, anatomically toxins from it could enter the 
CNS to instigate MS. A significant elevation of anti-D. pigrum was 
detected in the sera of MS patients when compared with a matched 
control group, and although these antibodies could not be linked 
specifically to MS by Western blotting further work on sequencing D.  
pigrum could lead to the development of primers capable of screening for 
toxins and antibodies to these and other bacterial products, which may 
provide evidence of a specific association between D.  pigrum, and other 
bacteria found in the nasopharynx, and MS.  If specific bacterial products 
linked to MS are thus identified then they could be used to develop 
ELISA tests to look for antibodies or, more excitingly, the bacteria could 
be looked for directly using a PCR test.  This test could be performed on 
non-invasive samples such as „nose blows‟.  The development of such a 
molecular test could lead to specific and early diagnosis, and possibly 
treatment, of the disease using, for example, specific monoclonal 
antibodies, before serious damage occurs to the brain and spinal cord. 
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Chapter 5:                                                  
Reflections on the Professional Doctorate 
 
 
 
Professional doctorates (PDs) are not new and the first professional practice 
doctorate was granted in Paris in the 12
th
 century (Bournier, Bowden & Lang, 
2001, pp. 65-83) many years before the first PhD in 1861 (Bournier, Bowden & 
Lang, 2000, pp. 226-237).  What drew me towards the professional doctorate was 
the fact that it could be studied part time and I therefore would not have to take a 
career break to complete it.  I saw it as a course that would gradually increase my 
skills in a journey of further and continuous development rather than a means to 
a fixed goal as a PhD would have been.  Although an increasing number of PhDs 
contain taught elements like PDs, these tend to be individualized based study 
programmes rather than cohort-based as is found with PDs.  This is an important 
issue as the support I found from the lecturing staff and classmates was integral 
to developing as a researcher and practioner in the difficult first few years of a 
doctoral programme. It was therefore traumatic to discover in Part 2 of the PD 
that this level of support was no longer available.  Despite being used to being 
self directed this was a difficult period, and the disadvantages attempting to 
perform research part time was magnified by the problems of Government 
induced change in the form of Transforming Pathology and by personal tragedy.  
I found the research project challenging, but developing the skills to plan, set up 
and manage a multi-site research project, plus the experience of gaining ethical 
approval, will directly benefit me when I undertake further research, and also 
enable me to offer guidance to colleagues in the future.  Having personally 
obtained all the research monies from a mixture of Institute of Biomedical 
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Science (IBMS) grants, research awards and charitable donations I have become 
more aware of sources for research funding.  I have also during the PD become a 
budget holder for these research monies which financed related research projects 
of a small group of researchers, including the MSc research project of Charles 
Gay which developed the PCR probes I utilised for my study at the University of 
Essex.  Without this developmental work I would have been unable to include 
the PCR part of the study because of the time restraints of conducting research on 
a part-time basis.  An article in the local newspapers, arranged through 
Colchester Hospital University Foundation Trust‟s Head of External Relations, 
Mark Prentice, reported that I had been awarded a research grant to research 
multiple sclerosis. This led to a local businessman contacting me to ask if he 
could help to purchase equipment for the research as he felt that the amount that I 
had been awarded was too small to research such an important subject.  It 
transpired that a friend of his had contracted multiple sclerosis and had been 
deteriotating rapidly, and he was desperate to fund research into the disease. I 
arranged for the money to be used as a charitable donation which enabled an 
expensive microscope camera to be purchased.  This has been used extensively 
by the research group for photographs in a number of published papers, the latest 
of which (Gay, 2013, pp. 213-232) gave an acknowledgement to me for 
bacteriological and administrative help.  Using the administrative skills I have 
gained in planning and setting up my doctoral project I have assumed 
responsibility for the receipting of goods for the Microbiology Department, 
Colchester, and have written a database for the recording of standing orders, as 
well as becoming a signatory for non-stock requisition ordering for the 
department.  
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In general it is widely held that a PhD is designed to prepare the student for a 
career in academia by breadth and originality of research, whilst a PD, although 
equal in rigour, is intended to further the career of experienced practioners in a 
specific field.  To this end a PD research project tends to be problem focused and 
concentrated on the application of theory and knowledge to a particular 
profession, whilst a PhD project is involved in trying to create new theories or 
knowledge. Hambrick (1997, pp. 133-148) has argued that for a professional 
doctorate to educate only for practitioner roles is too limiting. Certainly my 
project is not a typical professional doctorate project as it is not based on the 
premise of answering a problem in my practice.  It has elements of a PhD as it is 
involved in furthering the knowledge of MS and has elements of originality as it 
proposes a new hypothesis for the pathogenesis of this little understood disease 
(Jorge, 2009a, pp. 573-577).  Yet it also has elements of a PD project as it 
addresses professional practice problems in medical microbiology such as the 
optimal method of isolating and identifying slow growing potential pathogens 
such as D.   pigrum, which can pose a significant clinical problem.  The creation 
of novel enzyme linked immunosorbent assays (ELISA) and polymerase chain 
reaction (PCR) tests for the project also helped me to understand these 
procedures which are becoming increasingly important as medical microbiology 
moves from traditional manual cultural methods to automated techniques, and 
from biochemical identification to use of molecular biology and mass 
spectrometry to characterise and speciate micro-organisms.  I now feel better 
able now to impart knowledge and understanding of these new techniques that 
are rapidly shaping the provision of the services of medical microbiology in the 
21
st
 century to other microbiology staff members.  
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This understanding, and the skills I have gained from the taught modules of the 
PD, have thus not only helped me directly as a practitioner but with training and 
educating microbiology staff and students from the University of Essex, 
something which I have become more active in since I started the PD.  I now 
lecture and run practicals for undergraduates at the University of Essex on the 
biomedical sciences course, and have helped to set up their MSc course, on 
which I give lectures on the microbiology units, and set questions for the final 
examinations.  I have also begun running a „summer school‟ week for the 
undergraduates in pathology and mark their assessed essays, reflective diaries 
and presentations.   
Another area that the PD has improved me as a practitioner is in publication and 
dissemination.  Prior to beginning the course I had not considered publication, 
but inspired by the PD I published two articles (Jorge, 2009a, pp. 573-577; Jorge, 
2009b, pp. 125-126) and will look to write more.  The first of these articles led to 
an invitation to give a presentation to the London and South East Region 
(LASER) conference “Brave New Workforce” in Brighton on the 4th and 5th June 
2009, where I explained about my project, and argued for the usefulness of PD, 
detailing my experiences and research project.  I concluded that it was a 
worthwhile degree for the individual development of experienced biomedical 
scientists with benefits for the practitioner, profession and employers.  Whilst at 
this conference I met Keith Kitson who had been writing on critical reflection in 
biomedical science (Kitson, 2005) and this inspired me to regularly lecture on the 
subject to the University of Essex undergraduate students.  One of the problems 
cited at a recent biomedical science meeting at the University of Essex was the 
difficulties some students had with the reflective diaries needed for their 
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portfolios and I have expressed an interest in lecturing and running workshops on 
this subject for the students.   
Although my research project does not prove the bacterial toxin hypothesis it 
does not disprove it.  The complete sequencing of the genome of both D. pigrum 
and staphylococci will enable the production of specific primers to look for the 
presence of the bacteria and their toxins in multiple sclerosis.  This could be done 
using PCR on both serum and CSF in case control studies.  Animal experiments 
using a range of toxins should also be carried out, and markers using, for 
instance, current therapeutic agents, added to the nose of human volunteers, both 
MS and matched controls, and tracked using magnetic resonance imaging could 
also be used to establish if the bacterial toxins hypothesis is valid.  I hope that my 
work will be used to continue research into MS and the bacterial toxins 
hypothesis.  For this to happen it is important to disseminate my results.  To this 
aim I have given a series of four presentations to the microbiology department.  
The first presentation outlined the history of MS and explained what the disease 
is and current thoughts on diagnosis and treatment.  The second examined 
current hypotheses on the cause of MS and explained the bacterial toxins 
hypothesis on which my current research is based.  The third explained how PCR 
works and the results from my project and the fourth explained the principles of 
ELISA and Western blotting and detailed the results from my project.  I also 
hope to publish my doctoral research in a peer reviewed journal such as the 
British Journal of Biomedical Science.  I have also been contacted by Mark 
Prentice again, who interviewed me and a member of the research team, Derek 
Gay, about including news of our research into MS in an internal newsletter, 
Mainstream.  Mark was particularly interested in the history of the research as it 
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all began in microbiology in Colchester in 1986 when Derek started work as an 
independent researcher here.  It was also agreed to put out a press release to the 
local newspapers to coincide with the publication of Derek Gay‟s paper in the 
scientific journal Multiple Sclerosis and Related Disorders (Gay, 2013, pp. 213-
232) about the MS research that had taken place using monies won as a research 
prize from Colchester Hospital University Foundation Trust. Mark was 
particularly keen to stress the fact that I worked for the trust, and to highlight the 
research for my PD.  This publicity and the publication of my research findings, 
and Derek‟s paper, will promote the hypothesis of a bacterial cause of MS, and 
will hopefully lead to more research that may lead to a diagnostic test for MS and 
an effective prophylaxis and/or treatment for this dreadful disease.  
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A1 Ethics 
 
 
Essex 2 Research Ethics Committee 
Terminus House 
9th Floor 
The High 
Harlow 
Essex 
CM20 1XA 
 
Telephone: 01279 419312  
Facsimile: 01279 694917 
10 February 2008 
 
Mr Mark Francis Jorge 
Senior Biomedical Scientist 
Essex Rivers Healthcare Trust 
Microbiology Department 
214 Turner Road 
Colchester 
CO4 5JR 
 
Dear Mr Jorge 
 
Full title of study: The potential pathogenicity of Dolosigranulum pigrum in Multiple 
Sclerosis, and the occurance of the organism in the upper respiratory 
tract. 
REC reference number: 08/H0302/4 
 
Thank you for your letter of 24 January 2008, responding to the Committee‟s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair in 
consultation with the lead readers for your study. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation as 
revised. 
 
Ethical review of research sites 
 
 The Committee has designated this study as exempt from site-specific assessment (SSA.  There 
is no requirement for [other] Local Research Ethics Committees to be informed or for site-
specific assessment to be carried out at each site. 
 
Conditions of approval 
 
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document.  The committee also request that you notify the coordinator of the registration 
number for the Registered Tissue Bank which will be used to supply tissue for this study. You are 
advised to study the conditions carefully. 
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Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Application  Version 5.5  11 December 2007  
Investigator CV    10 December 2007  
Protocol  Version 5.0  23 January 2008  
Covering Letter    10 December 2007  
Summary/Synopsis  Version 3.0  04 December 2007  
Letter from Sponsor    27 November 2007  
Response to Request for Further Information    24 January 2008  
CV Dr D R Memagh Supervisor    28 November 2007  
Risk Assessment Dept Biological Services       
Dept of Microbiology COSHH       
Employee Risk Assessment Form R024       
General Risk Assessment Form R50       
General Risk Assessment Form R023       
Emails from Queries Line NRES    05 June 2007  
 
R&D approval 
 
All researchers and research collaborators who will be participating in the research at NHS sites 
should apply for R&D approval from the relevant care organisation, if they have not yet done so.  
R&D approval is required, whether or not the study is exempt from SSA.  You should advise 
researchers and local collaborators accordingly. 
 
Guidance on applying for R&D approval is available from 
http://www.rdforum.nhs.uk/rdform.htm. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National Research Ethics 
Website > After Review  
 
Here you will find links to the following 
a)   Providing feedback. You are invited to give your view of the service that you have 
received from the National Research Ethics Service on the application procedure. If you 
wish to make your views known please use the feedback form available on the website. 
b)   Progress Reports. Please refer to the attached Standard conditions of approval by 
Research Ethics Committees. 
c)   Safety Reports. Please refer to the attached Standard conditions of approval by Research 
Ethics Committees. 
d)   Amendments. Please refer to the attached Standard conditions of approval by Research 
Ethics Committees. 
e)   End of Study/Project. Please refer to the attached Standard conditions of approval by 
Research Ethics Committees. 
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We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencegroup@nationalres.org.uk . 
 
 
08/H0302/4 Please quote this number on all correspondence 
 
With the Committee‟s best wishes for the success of this project 
 
Yours sincerely 
 
 
 
Mr Jon Gould 
Chair 
 
Email: suzanne.emerton@eoe.nhs.uk 
 
 
Enclosures: Standard approval conditions 
 
 
Copy to: Dr Graham  Mills 
University of Portsmouth 
School of Pharmacy & Biomedical Science 
Room 2 
25 St Michaels Building 
White Swan Road 
Portsmouth 
PO1 2DT 
 
Essex Rivers Healthcare Trust R & D office  
 
 
 
 
 
 
 
Essex Rivers Healthcare Research and Development Reference No: 2007/038 
The Research and Development Steering Group gave approval for the project on the 14
th
 
February 2008. 
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Dear Mark, 
  
Ethical approval has been granted and work can proceed, but would you please 
send another couple of signed copies (pages 1 and 2) of the University form as 
before. 
  
Thank you, 
  
Terry 
 
Dr. Terry J. McGenity  
Department of Biological Sciences,  
University of Essex, Wivenhoe Park, 
Colchester, CO4 3SQ, UK    
T. +44 (0)1206 872535,  F. +44 (0)1206 872592  
email TJMcGen@essex.ac.uk 
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Appendix B: Reagents and materials 
 
 
B.1 Reagents for DNA extraction using PureLink DNA kits from 
Invitrogen (K1820-01) 
 
PureLink Genomic Lysis/Binding Buffer 
Lysozyme (Sigma, L6876) 
PureLink Genomic Digestion Buffer 
PureLink Proteinase K (20 μg ml-1) 
PureLink Wash Buffer 1 
PureLink Wash Buffer 2 
PureLink Elution Buffer 
 
 
 
 
B.2 Electrophoresis Reagents and materials 
  
Agarose (Fisher Scientific BP1356-100) 
Tris-Acetate- EDTA (TAE) buffer for agarose: 
TAE x 50 stock solution, containing: 
Tris base, 121 g 
Glacial acetic acid, 28.55 ml 
0.5 M EDTA (pH 8.0). 50 ml 
 
Loading dye for gel electrophoresis (Fisher Scientific) 
10 mM Tris-HCl (pH 7.6) 
Bromophenol blue, 0.03% w/v  
Xylene cyanol FF, 0.03% v/v 
Glycerol 60% v/v 
EDTA. 60 mM  
 
DNA ladder, Fermentas, GeneRuler SMO333  
TAE buffer. 
242 g TRIS base, 57.1 ml glacial acetic acid, 100 ml 0.5 ml EDTA, (pH 8.0) 
made up to 1 litre. 
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B.3 Gene Ruler DNA Ladder Mix 
 
 
 
 
Fermentas Life Sciences. #SMO333. 
This shows the relative positions of the different size DNA reference fragments.  
This DNA ladder has been used for all the experimental gels. 
 
 
B.4 Dolosigranulum pigrum ELISA reagents and materials 
Rabbit 6 anti-D  .pigrum pre and post immune serum 
Chicken egg albumin – Sigma A-5503 
BBL FTA haemagglutination buffer (Phosphate buffered saline pH 7.2 +/- 
0.1) -  Becton Dickinson 211248 
Brain Heart Infusion – Oxoid (CM0225) 
Tetramethylbenzadine buffer/chromagen (TMB) - BioRad 492430 
Anti-Rabbit IgG (whole molecule) peroxidase conjugate – Sigma A6154 
Anti-Human IgG (-chain specific) peroxidase conjugate – Sigma A6029 
Stopping solution (1 N sulphuric acid) 
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Sterilin Microtitre Plate (96 well, flat bottom – 611 F96) 
Sterilin polystyrene round bottom tubes (75 x 13 mm – 30924) 
Triturus 4 plate robotic EIA analyser – Grifols USA 
 
 
 
B.5 Western Blotting Reagents and materials 
Mini-Protean II dual slab cell – Bio-Rad 
Goat anti-human  IgG – Sigma Aldrich  18885 
Anti-goat horse radish peroxidase – Sigma Aldrich 12136 
Diaminobenzidine (DAB) enhanced liquid substrate system for  
membrane ELISA – Sigma Aldrich D6815 
Nitrocellulose membranes O.45 microns - Sigma-Aldrich N8267-5EA.   
Pre–cut filter paper - Bio-Rad 170-3932 
Acrylamide - Sigma Aldrich A3553 
Tris(hydroxymethyl)aminomethane – Sigma Aldrich 252859 
Sodium dodecyl sulphate - Sigma Aldrich L3771 
Mercaptoethanol - Sigma Aldrich M3148 
Ammonium persulphate - Sigma Aldrich A3678 
Methanol - Sigma Aldrich M3641 
Phospate buffer saline (PBS) tablet - Sigma Aldrich P4417 
Stock solutions 
Acrylamide/Bis (30% T, 2.67% C) 
87.6 g Acrylamide (29.2 g/100 ml) 
2.4 g NN – Bis – methylene-acrylamide (0.8 g /100 ml) 
Made to 300 ml with distilled water. Filter and stored at 4 °C in the dark (30 days 
maximum). 
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Sample buffer (SDS reducing buffer) stored at room temperature 
Distilled water 4.0 ml 
0.5M Tris-HCL, pH 6.8 1.0 ml 
Glycerol 0.8 ml 
10% (w/v) Sodium dodecyl sulphate SDS 1.6 ml 
2- mercaptoethanol 0.4 ml 
0.005% (w/v) Bromophenol blue 0.2 ml 
Electrode (running) buffer (X5), pH 8.3. Stored at 4 °C 
Tris base 9 g 
Glycine 43.2 g 
Sodium dodecyl sulphate (SDS) 3 g 
Made up to 600 ml with distilled water. Warm to 37 °C before use if 
precipitation occurs. Dilute coml. 5X stock with 240 ml for one electrophoresis 
run. 
Separating gel preparation 
Distilled water 3.35 ml 
1.5 M Tris-HCL, pH 8.8 2.5 ml 
10% (w/v) SDS stock 100 ml 
Acrylamide/Bis (30% stock) 4 ml 
10% ammonium persulphate 50 l 
Tetramethylethylenediamine (TEMED) 5 l 
Stacking gel preparation 4% gel, 0.125M Tris, pH 6.8  
Distilled water  6.1 ml 
0.5 Tris-HCL, pH 6.8 2.5 ml 
10% (w/v) SDS 100 l 
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Acrylamide/Bis 1.3 ml 
10% ammonium persulphate 50 l 
TEMED 10 l 
Transfer/equilibration buffer 
Tris 3.03 g 
Glycine 14.4 g 
De-ionised water  
Methanol v/v 200 ml 
pH 8.3 
Use at 4 °C 
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Appendix C 
Companies 
Axis-Shield Diagnostics Limited, The Technology Park, Dundee, DD2 1XA 
Fermentas Life Sciences, Sheriff House, Sheriff Hutton Industrial Park, York 
YO60 6RZ 
Fisher Scientific, Bishops Meadow Road, Loughborough, Leicestershire, LE11 
5RG 
Gene Service, 2 Cambridge Science Park, Milton Road, Cambridge CB4 0RE 
Invitrogen Limited, 3 Fountain Drive, Inchinnan Business Park, Paisley PA4 
9RF 
Oxoid Limited, Wade Road, Basingstoke, Hampshire, RG24 8PW 
Sigma-Aldrich Company Limited, The Old Brickyard, New Road, Gillingham, 
Dorset, SP8 4XT 
 
TCS Biosciences, Botolph Claydon, Buckinghamshire MK18 2LR, HBO34 
 
Qiagen, Qiagen House, Fleming Way, Crawley, West Sussex RH10 9NQ 
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Appendix D 
Original identification of Dolosigranulum pigrum 1989-1993 
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Dolosigranulum pigrum 
Accession Number: 702975 
Species Name: Dolosigranulum pigrum 
Strain Name: R91/1468  
Other Collection: ATCC51524 CIP104051 IFO15550 NCFB2975 
Date of Accession: 01/01/1992 00:00:00 
Depositor Company: PHLS 
Type Strain: Yes  
Reference: 44:370 
Isolated from: human spinal cord, Colchester, UK 
K12: Yes  
ACDP: 1  
 
Other Catalogue Information 
Former NCFB organism 
Growth 
Growth Medium: Todd Hewitt Borth (Oxoid) 
Growth Medium No: 361 
Incubation Temp: 37C 
Gas Regime: facultative anaerobic 
 
References 
J. Appl. Bact. (1993) 75, 608-612 IJSEM (2002) 52:1122 IJSEM (2005) 55:1326 IJSEM (2005) 
55:348 
 
 
http://www.ncimb.com/results.php?parent=culture 
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Appendix E 
 
 
Preparation of anti-Dolosigranulum pigrum antisera 
The rabbit anti-sera R3-R6 were prepared by Professor G.W.A. Dick at the 
Animal Unit facility of the University of Surrey under Home Office regulations. 
R3 and R4 were inoculated using a bacterial suspension in phosphate buffered 
saline (PBS) from an 8 day confluent growth of D.  pigrum on nutrient agar 
(Oxoid CM3).  R4 and R5 were inoculated with a suspension of cells, deposited 
by centrifugation, from a 6 day brain-heart infusion broth (Oxoid CMO225) 
culture which had been washed three times in PBS.   
Immunization schedules, after a pre-immunization bleed, started with an 
intramuscular injection of 0.5 ml cell suspension in 0.5 ml complete Freund‟s 
adjuvant. Intravenous booster immunizations were carried out at 4 weeks and at 
3 months. Sera were tested and titrated using an indirect immuno-fluorescence 
assay, followed by SDS-PAGE and Western Blotting. Antibody was detected, 
titrated and analyzed in all four rabbit sera. No reactivity was detected in pre-
immune sera. Sera were absorbed with the bacterial cells, in four cycles, 
resulting in a progressive fall in titre.  The sera were used for 2 published papers 
(Aguirre et al., 1993, pp. 608-612; Gay, 2013, pp. 213-232) as well as this 
project. 
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